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BACKGROUND AND RESEARCH GOALS 
 
Introduction 
 The constant threat of microbial invasion and pathogenesis forces the host to 
depend on a powerful army: the immune system.  Whereas innate immunity provides 
rapid protection, adaptive immunity generates responses that are highly specific to 
individual pathogens.  Mounting effective immune responses against an unrelenting and 
changing sea of infectious agents requires broad repertoire specificity potential.  This 
diversity comes at a price however, as many of the randomly generated specificities may 
recognize self.  Such autoreactivity, if not appropriately controlled, can result in 
autoimmune disease development.  Regulation or “tolerance” is thus imposed on immune 
cells to keep their destructive potential from being unleashed on the host, while 
preserving anti-microbial recognition.  A failure to adequately maintain tolerance 
underlies the presence of autoimmune diseases that manifest in a diverse range of 
pathologies that plague the human population.  Available therapeutics for many of these 
diseases often show limited efficacy and are frequently ineffective at reversing immune-
mediated destruction.  The goal of this thesis work is therefore to better understand how 
tolerance mechanisms play a role in culling autoreactive B cell specificities that occur in 
the developing B cell repertoire and thus provide insight into possible avenues for 
medicinal intervention. 
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B Cell Development and Function 
 
B Cell Developmental Progression 
In 1958, Nossal and Lederberg showed that a single B cell produces a single 
antibody (Ab) specificity (134).  Subsequently, F. Macfarlane Burnet proposed the clonal 
selection theory in 1959 (25).  Monospecificity of the B cell receptor (BCR), which 
interacts with antigens (Ags), is a key element that allows B cells to participate in 
adaptive immune responses.  B cell development proceeds in an ordered, highly regulated 
fashion which aids in the generation of monospecific B cells, a process known as allelic 
exclusion (146).  B cells begin life in the bone marrow as pluripotent progenitor cells, 
and differentiate from hematopoetic stem cells to multilineage progenitors to common 
lymphoid progenitors to pre-pro-B cells, where they are first committed to the B cell 
lineage (70).   
Stages of early B cell development are predominantly defined by immunoglobulin 
(Ig) gene rearrangement.  Ig heavy (IgH) and light (IgL) chain gene rearrangement is a 
highly ordered and regulated process.  At the pro-B cell stage, a diversity region of IgH 
(DH) segment joins to a joining region of IgH (JH) segment, followed by rearrangement 
of a variable region of IgH (VH) to DH-JH through a process called V(D)J recombination 
(6, 185).  Deletion of either recombination activating gene (RAG)-1 or RAG-2 proteins 
involved in Ig recombination results in failure of the B cell to progress beyond the pro-B 
cell stage, and ultimately the absence of B and T cells (124, 175).  Once the IgH gene 
segments are successfully rearranged, IgH pairs with the surrogate light chain and is 
expressed on the surface of the B cell as the pre-BCR, which defines the transition into 
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the pre-B cell stage (6).  The surrogate light chain is encoded by λ5 and Vpre-B (91, 166).  
Expression of the rearranged IgH allows progression to the pre-B cell stage (48), and a 
loss of surrogate light chain and endogenous light chains results in a block at the pro-B 
cell stage (141, 144).  Signaling from the pre-BCR negatively regulates RAG expression 
(65) and surface expression of the pre-BCR reduces chromatin accessibility of the IgH 
gene segments to RAG (39, 183), both of which function as a mechanism for maintaining 
allelic exclusion.  Asymmetric demethylation of one of the IgL alleles also likely 
enhances allelic exclusion by increasing chromatin accessibility of the demethylated 
allele to RAG (126). 
Upon successful expression of IgH, cells undergo proliferation at the large pre-B 
cell stage and then enter the small pre-B cell stage and re-express RAG (49, 101, 162).  
IgL gene rearrangement then initiates, and involves the joining of variable region of IgL 
(VL) and joining region of IgL (JL) gene segments (188).  A successfully rearranged IgL 
can pair with the IgH to form a mature BCR that is expressed on the surface of the cell, 
denoting transition into the immature B cell stage (49, 101).  However, it has been shown 
that light chain rearrangement can also take place in μMT mice that lack membrane-
bound μ chains (86), and a proportion of wild-type (WT) CD43+ pro-B cells show 
rearranged VL-JL genes prior to VH-DH-JH gene rearrangement (49, 136), suggesting 
that a functionally rearranged IgH is not required for the initiation of IgL rearrangement.  
An experimental model in which BCR expression is inducibly diminished results in 
“back-differentiation” of the cells, such that pro-B cell genes are re-expressed and V(D)J 
recombination genes are up-regulated (190). 
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An appropriate signal from the BCR on the surface of the immature B cell is 
required for continued development.  If this signal is absent, due to faulty pairing of the 
IgL with the IgH and thus insufficient BCR surface expression (21, 89), or if autoantigen 
(autoAg) engagement triggers BCR down-regulation, receptor editing, involving 
rearrangement of novel VL and JL gene segments, may be initiated (61, 152, 171, 187).  
Recombinational machinery activity is subsequently sustained to facilitate continued IgL 
rearrangement (31, 187), and decreased BCR surface expression has been shown to 
correlate with increased RAG expression (125, 171, 204).  Upon successful surface 
expression of a BCR, immature B cells exit the bone marrow and enter the spleen as 
transitional B cells, and further develop into the mature B cell stage after 4 days (5, 139).  
Transitional 1 (T1) cells undergo apoptosis, whereas T2 B cells proliferate following 
BCR signaling, due to BAFF receptor expression in T2 B cells which leads to enhanced 
survival signaling (12, 148).  The various stages of B cell development can be identified 
through differential cell surface marker expression, which is depicted in Table 1-1 and 1-
2. 
 
Immunoglobulin Transgenes Alter B Cell Developmental Progression 
BCR Ig transgenic (Tg) models have produced key insights into B cell 
physiology, as they facilitate the study of how Ag interaction influences B cell biology by 
restricting the polyclonal repertoire to a single, known Ag specificity.  Monospecificity is 
accomplished by providing functionally rearranged IgH and IgL Tgs, which, due to their 
completed rearrangement status, are dominantly expressed over endogenous IgH and IgL, 
which would require successful V(D)J recombination to occur for expression.  While 
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Table 1-1.  Identification of B Cell Developmental Stages Present in Bone Marrow 
Using Differential Cell Surface Marker Expression 
Cell Surface 
Marker 
Pro Pre Immature Mature 
Recirculating 
CD19 + + + + 
B220 + + + ++ 
CD43 + - - - 
IgM - - + + 
AA4.1 - - + - 
CD21 - - - + 
CD23 - - - + 
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Table 1-2.  Identification of B Cell Developmental Stages Present in Spleen Using 
Differential Cell Surface Marker Expression 
Cell Surface 
Marker 
Transitional Follicular Marginal Zone 
CD19 + + + 
B220 + + + 
CD43 - - - 
IgM + + + 
AA4.1 + - - 
CD21 + ++ +++ 
CD23 + +++ ++ 
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such Tgs greatly expand the array of questions that can be tested, some alterations to 
normal B cell development occur and are important to note.  Functionally rearranged IgH 
and IgL Tgs expedite B cell developmental progression to the IgM+ immature B cell 
stage (120).  Whereas knocking out RAG-1, RAG-2, or µ heavy chain arrests B cell 
development at the pro-B cell stage (87, 124, 175), the presence of a functionally 
rearranged IgH Tg alleviates this developmental block and allows B cells to reach the 
pre-B cell stage, and the additional presence of a functionally rearranged IgL Tg 
completely alleviates the developmental block (182, 202). 
 
Mechanisms that Generate B Cell Receptor Specificity Diversity 
V(D)J recombination is estimated to generate >1011 specificities, due to the 
myriad of potential combinations of VH, DH, and JH gene segments for the IgH, or VL 
and JL segments for the IgL, termed combinatorial diversity, as well as junctional 
diversity arising from differences in the joints between the gene segments (reviewed in 
80).  P- and N-nucleotide additions also enhance diversity at gene segment joining 
regions, as do nucleotide deletions (reviewed in 80).  Terminal deoxynucleotidyl 
transferase (TdT) is the enzyme responsible for adding non-templated N-nucleotides at 
the DH-JH and VH-DH junctions during IgH rearrangement (92), whereas palindromic 
P-nucleotides result from RAG-mediated cleavage of the hairpin loops (115).  Additional 
diversity and enhanced Ab affinity is achieved through somatic hypermutation, a process 
which introduces point mutations into the germ line encoded DNA of Ig genes to result in 
affinity maturation (reviewed in 103). 
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B Cells and their Role in Generating Immune Responses 
The mature B cell pool is made up of many different B cell subsets.  B-2 B cells 
reside in the spleen, and are subdivided into follicular and marginal zone B cells 
(reviewed in 95).  Follicular B cells are located in the follicle next to the T cell zone, and 
clonal interaction with T cells promotes the formation of germinal centers (reviewed in 
95).  Marginal zone B cells are present in the marginal zone and are ideally positioned to 
encounter blood-born pathogens (113).  B-1 B cells are located in the pleural and 
peritoneal cavities and are thus ideally located to encounter gut and peritoneum Ags, and 
are responsible for generating the majority of circulating Ab (83, 113).  B-1 and marginal 
zone B cells can generate rapid, T-independent responses to Ag (137), and thus function 
in an innate-like capacity (112).  B-1 B cells are thought to have self-renewal capacity, 
and marginal zone B cells are long-lived; in contrast, the follicular B cell pool depends on 
continual influx of immature B cells from the bone marrow for homeostatic maintenance 
of this population (29, 69). 
 
The Effects of Different Antigen Characteristics on Immune Activation of B Cells 
Many characteristics of Ag engagement of the BCR influence the activation 
outcome of the cell.  Increased Ag concentration and avidity, enhanced affinity of the 
BCR for the Ag, as well as the presence of co-stimulatory signals enhance the activating 
potential of the Ag (reviewed in 73).  A classic example of how the nature of a given Ag 
can modify the manner in which the immune system responds is the immunogenic or 
“tolerogenic” effects of aggregated or de-aggregated IgG (35, 45).  T cell help (37), 
“danger signals”, which emanate from pattern recognition receptors such as Toll-like 
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Receptors (TLRs) (107), or stimulation through complement receptors (28, 55) all 
enhance the stimulatory potential of a given Ag by signaling that it is associated with a 
pathogenic invader.  The timing of when Ag is encountered during B cell development 
also influences whether a B cell is activated; BCR triggering during development 
typically elicits tolerance, whereas cellular activation is more likely to occur if Ag is 
encountered once the cell has matured (reviewed in 73). 
 
B Cell Receptor Signal Transduction 
 
B Cell Receptor Signaling 
Work by many groups as well as work presented in this thesis demonstrates that B cells 
are exquisitely sensitive to Ag engagement of the BCR and are finely tuned to respond in 
a multitude of ways depending on subtle changes that are both quantitative and 
qualitative in nature.  The network of molecules involved in diverse signaling cascades is 
highly complex and interwoven, and for simplicity and relevance, much of this will not 
be discussed.  Engagement of the BCR results in ER Ca2+ release from the ER (reviewed 
in 59).  Depletion of the ER Ca2+ store leads to extracellular Ca2+ influx, which promotes 
a sustained increase in intracellular Ca2+ (142).  This can lead to calmodulin and 
calcineurin activation of nuclear factor of activated T cells (NFAT) (reviewed in 41). 
 
Differences in Immature and Mature B Cell Signaling 
B cell maturation triggers important differences in how the cell responds to Ag 
engagement, and these responsive changes are pivotal in balancing effective B cell 
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immunity with tolerance to self.  In 1975, differential sensitivity of immature (neonatal-
spleen derived) versus mature (adult spleen-derived) B cells to IgM crosslinking was 
observed, providing the first evidence for differential sensitivity of immature and mature 
B cells (153, 177).  Immature B cells showed irreversible IgM down-regulation and 
higher sensitivity to the concentration of IgM, whereas this down-regulation was 
reversible in splenic B cells upon anti-IgM removal (153, 177).  Following identification 
of cell surface markers which identify developing B cells, such studies confirmed that 
IgM crosslinking of the BCR induces cell death in immature B cells, whereas mature B 
cells proliferate (32, 133, 201).  Specifically, this change has been shown to take place 
between the T1 and T2 transitional B cell stages in the spleen (148).   
Despite up-regulating cyclin D2 and cyclin dependent kinase 4 (CDK4) to 
promote G1 entry, BCR crosslinking of immature B cells fails to up-regulate cyclin E, 
which thus impairs formation of cyclin E/CDK2 complexes required for cell cycle 
progression (26).  In addition to stimulating proliferation, BCR stimulation of mature B 
cells results in up-regulation of the activation markers CD69, CD86, and major 
histocompatibility (MHC) class II, whereas immature B cells show no up-regulation of 
these molecules (14).  Immature B cells are more sensitive to BCR signaling, as lower 
increases in intracellular calcium are necessary to induce RAG induction in immature B 
cells than to up-regulate activation markers such as CD86 and MHC class II on mature B 
cells (14).   
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Autoreactivity in the B cell Compartment 
 
Prevalence of Self-Reactivity in Developing B Cells 
Each day, ~20 x 106 cells are produced in the bone marrow of a mouse (138).  
V(D)J recombination ensures that a tremendous potential for generating repertoire 
diversity exists, however the cost of this diversity is that autoreactive as well as useful 
specificities are generated.  In humans, 55-75% of newly formed B cells are estimated to 
be autoreactive (193).  Additional evidence in mice for a rather high propensity towards 
generating autoreactive specificities in the bone marrow is that only 10-20% of immature 
B cells formed in the bone marrow survive the maturation process long enough to 
emigrate from the bone marrow, and only 3% survive as mature B cells in the periphery 
(5, 57, 69, 164).  This deletion is specific, as the repertoire of specificities is altered 
between immature and mature B cell populations, suggesting a selection event (66, 153, 
168).  The induction of tolerance in the nascent B cell compartment is known to occur 
upon BCR engagement; immature and transitional B cells undergo tolerance induction in 
the absence of additional signals, such as T cell help (4, 27, 58). 
 
The Role of B Cells in Autoimmune Disease Development 
Preservation of tolerance in developing and mature B cell compartments is critical 
for the prevention of autoimmune disease.  B cells that escape tolerance can generate 
pathogenic Abs, which have been demonstrated to play a role in autoimmune diseases 
such as systemic lupus erythematosus (SLE), Goodpasture’s syndrome, hemolytic 
anemia, Graves’ disease, thrombocytopenic purpura, myasthenia gravis, and pemphigus 
 12
vulgaris (111, 127).  Detection of autoantibodies (autoAbs) is also common in patients 
with autoimmune diseases which result from T cell-mediated destruction, such as 
Hashimoto’s thyroiditis, type I diabetes (T1D), and rheumatoid arthritis (127).  
Rituximab, which targets B cells, has been approved for the treatment of rheumatoid 
arthritis, suggesting an indirect role for B cells in disease (reviewed in 118).  In addition 
to showing efficacy for rheumatoid arthritis, Rituximab treatment has also shown promise 
for treating hemolytic anemia and thrombocytopenic purpura (47, 74, 75, 147).  
Rituximab clinical trials for T1D efficacy are currently underway.  The ability of B cells 
to mediate autoimmune disease is not restricted to the generation of pathogenic autoAbs.  
Additional B cell functions, such as presenting of autoAgs to autoreactive T cells, have 
also been attributed to disease pathogenesis (174). 
Multiple checkpoints exist in healthy patients that serve to remove autoreactive 
specificities generated in the bone marrow; however these checkpoints are dysregulated 
in patients with SLE, thus permitting escape of autoreactive cells into the periphery (167, 
205).  These findings suggest that central tolerance defects may promote the development 
of human autoimmune disease (167, 205), thus highlighting the importance of 
understanding how these mechanisms function or fail in healthy or diseased individuals, 
respectively.  In addition to mediating systemic autoimmune diseases, such as SLE, 
autoreactive B cells have also been shown to play a role in organ-specific autoimmune 
diseases, such as T1D (3, 78, 132, 173, 179). 
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Importance of B Cells in the Development of T1D in the NOD Mouse 
According to the American Diabetes Association, diabetes is characterized by 
blood glucose levels in excess of 200mg/dL, elevated fasting blood glucose, and impaired 
oral glucose tolerance.  Patients often experience weight loss, thirst, polyuria, polydypsia, 
visual blurring, and weight loss.  This results from destruction of β cells in the pancreas, 
which impairs the ability of the pancreas to produce insulin in response to elevated blood 
glucose.  By the time T1D patients present with overt disease, ~90% of beta cell function 
has already been lost, thus highlighting the importance of disease prediction (reviewed in 
44).  The presence of insulin (140), glutamic acid decarboxylase (GAD) (8, 9), and/or 
protein tyrosine phosphatase-related IA-2 molecule (IA-2) (36, 143, 151, 180) islet cell 
autoAbs have all been found to be predictive of T1D development, and are the first 
indicators of β cell-targeted autoimmunity.  Insulin autoAbs are predictive of disease 
development in T1D-prone non-obese diabetic (NOD) mice in addition to humans, and 
thus represent an important risk factor (203).  T cell-mediated destruction of insulin-
secreting beta cells in pancreatic islets results in uncontrolled elevation of blood glucose 
levels found in T1D patients (18, 19, 62).  B cells do not directly mediate beta cell 
destruction; however they play an indirect role in the progression of diabetes, as T1D-
prone NOD mice that lack B cells (μMT) are protected against developing T1D (3, 173), 
and treatment with anti-IgM Ab is also protective (132).  B cells have additionally been 
shown to play indirect roles in disease, such as in T1D, in which they likely function to 
present autoAgs to autoaggressive T cells (174).  Restricting the B cell repertoire with the 
use of B cell Tgs that bind irrelevant (non-self) Ags also protects against T1D (78, 179).  
However, mice which possess an anti-insulin BCR IgH Tg (VH125Tg) or IgH and IgL 
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Tgs (125Tg) develop T1D (78), thus providing a tractable model in which the role of Ag-
specific B cells in disease development can be addressed. 
 
B Cell Tolerance Mechanisms 
B cell tolerance maintenance is critical because autoreactive specificities are 
continually generated.  Checkpoints therefore exist that exert control throughout all 
stages of B cell maturation.  Central tolerance describes the mechanisms that act during B 
cell development in the bone marrow, and include receptor editing and deletion (61, 128, 
130, 152, 187), and, as demonstrated in Chapter II, anergy.  Receptor editing “edits” the 
autoreactive BCR (and maintains allelic exclusion) by rearranging a novel IgL, which 
replaces the autoreactive IgL.  “Deletion” of the autoreactive clone from the repertoire 
through programmed cell death ensures that tolerance is maintained if receptor editing 
fails (68).  Anergy results in functionally impairing various functions of the B cell which 
preclude it from actively participating in immune responses (64).   
Due to the high degree of autoreactivity that originates in the developing B cell 
compartment (193), central tolerance represents a critical point of control.  In the event 
that central tolerance fails to adequately censor autoreactive B cells, peripheral 
mechanisms of tolerance also exist to further limit the dangerous potential of self-reactive 
clones.  As additional mechanisms of diversity such as somatic hypermutation function in 
the mature B cell compartment to create further possibilities for the generation of 
autoreactive receptors (15, 194), such peripheral checkpoints are critical in preventing 
potentially harmful immune responses.  Mechanisms of peripheral B cell tolerance 
include anergy and deletion (64, 128, 130). 
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B Cell Anergy 
Allowing autoreactive B cells to remain in the mature B cell repertoire may 
promote autoimmune disease, however, overly stringent removal of potentially dangerous 
specificities risks reducing repertoire diversity and thus could impair effective pathogen 
clearance.  A solution to this problem involves a tolerance mechanism called anergy, in 
which autoreactive B cells remain, thus preserving repertoire diversity, but they are 
functionally impaired, thereby limiting their ability to promote destruction of self.  Under 
appropriate conditions that suggest immunogenic necessity for the specificity (discussed 
below), anergy is reversible, allowing functional reinstatement of the B cell.   
Such functional unresponsiveness is characterized by the reduced ability to 
proliferate or differentiate into Ab-secreting plasma cells following BCR stimulation (43, 
64).  Anergic B cells are functionally unresponsive to further BCR stimulation, have a 
shortened lifespan in the periphery, and are excluded from B cell follicles (43, 155).  The 
presence of competitor B cells is required for this exclusion, as autoreactive B cells 
transferred into B cell-deficient animals do not display follicular exclusion (170).  
Survival of autoreactive B cells transferred into B cell deficient animals is enhanced by 
the presence of T cells, compared with those transferred into RAG-1-/- animals deficient 
for both B and T cells (170), suggesting that T cells may play a supportive role in the 
preservation of autoreactive specificities in lymphopenic animals, such as the NOD T1D 
model.  Active participation in immune responses is limited, as anergic cells do not 
produce significant levels of circulating Ab, even upon immunization (64, 131, 160).  Tg 
B cells specific for hen egg lysozyme (HEL) (IgHELMD4Tg) or insulin that encounter 
soluble Ag in vivo are rendered anergic (64, 160). 
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Anergic B cells can regain functionality when they are provided appropriate 
secondary signals, such as complement receptor engagement (which could be triggered 
by a complement-fixed pathogen) (108), or anti-CD40 or IL-4 stimulation (mimics of T 
cell help) (1, 40).  Chronic Ag engagement is also required to maintain this state, as 
transferring HEL-specific B cells into an HEL-free mouse (63), or competitive removal 
of the Ars/A1 model autoAg by arsonate hapten (13, 60) restores B cell functionality.  
Further evidence is presented in Chapter II to show that continued insulin exposure is 
necessary to maintain functional impairment in immature anti-insulin B cells. 
 
A BCR Transgenic Model Facilitates the Study of Immune Tolerance for Insulin 
Our lab utilizes a B cell Tg model (125Tg) in which anti-insulin IgH (VH125Tg) 
and IgL (Vκ125Tg) Tgs are randomly integrated into the genome to generate B cells, 
>95% of which bind insulin (160).  The 125Tg anti-insulin BCR has different affinities 
for insulin derived from different species (172).  Insulin is a highly conserved molecule, 
and this system allows the effects of altered affinity to be studied with minimal changes 
to the overall Ag structure.  We have demonstrated that the BCR of these cells is 
continuously occupied by circulating insulin in vivo; thus 125Tg animals are a useful 
BCR Tg model in which a physiologically relevant BCR:Ag interaction can be studied 
(160).  VH125 encodes an anti-insulin IgH, whereas VH281, which differs from VH125 
by two amino acids that confer insulin-binding, does not measurably bind to insulin when 
paired with anti-insulin Vκ125 (186).  VH125Tg and VH281Tg mice possess a 
rearranged IgH Tg that is randomly integrated in the genome, which pairs with 
endogenous IgLs to produce a BCR, which generates a polyclonal repertoire (186).  
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Table 1-3 outlines all of the Ig Tg genotypes studied in this dissertation as well their Ag 
specificities. 
Classically, hormones are expected to induce clonal ignorance, as they are soluble 
proteins present at low concentrations and thus may be “ignored” by the B cell due to 
insufficient stimulatory potential.  Surprisingly, 125Tg B cells are not clonally ignorant, 
but rather are rendered anergic in vivo (160), despite the fact that circulating insulin is 
present at very low concentrations (up to 1-5 ng/mL post-prandially (56)), insulin is a 
small, soluble protein and does not appreciably crosslink the BCR, and the affinity of the 
interaction is modest (7 x 106 M-1) (172).  This form of anergy is characterized by 
impaired Ca2+ mobility following acute stimulation in anti-insulin (125Tg) B cells as 
compared with non-tolerant B cells isolated from the spleen, and basal IP3 levels are 
reduced (2).  Tolerant 125Tg B cells do not show elevated intracellular Ca2+ or impaired 
tyrosine phosphorylation (2), as has been shown for the IgHELMD4Tg model (40, 72, 
191).  Anti-IgM stimulation of 125Tg spleen B cells results in decreased endoplasmic 
reticulum (ER) release of intracellular stores of Ca2+, and they are more sensitive to 
thapsigargin-induced ER Ca2+ store depletion, suggesting that sarcoendoplasmic 
reticulum Ca2+ ATPase (SERCA) pump expression and/or activity may be enhanced in 
these cells (2).  125Tg B cells show decreased basal levels of NFATc1 and impaired 
NFATc1 nuclear translocation following BCR or ionomycin stimulation (2).  Anti-insulin 
B cells fail to proliferate in response to stimulation with anti-IgM and they do not 
respond to T cell-dependent immunization (1, 160).  This state of functional inactivation 
also limits the contribution of Tg B cell-derived Abs to the pool of circulating Ab (160).
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Table 1-3.  Nomenclature and B Cell Antigen Specificities of Heavy and Light Chain Transgenes Present in Genotypes 
Studied 
Genotype Heavy Chain Transgene Light Chain Transgene Antigen Specificity in Repertoire 
WT None - endogenous None - endogenous Polyclonal 
VH125Tg Non-targeted, anti-insulin None - endogenous Insulin/Polyclonal 
VH281Tg Non-targeted, non-insulin-specific None - endogenous Non-insulin/Polyclonal 
VH125Tg/Vκ1ki Non-targeted, anti-insulin Targeted, anti-DNA Non-insulin/Polyclonal 
VH125Tg/Vκ4ki Non-targeted, anti-insulin Targeted, anti-DNA Non-insulin/Polyclonal 
VH125Tg/Vκ8ki Non-targeted, anti-insulin Targeted, anti-DNA Non-insulin/Polyclonal 
VH125Tg/Vκ125ki Non-targeted, anti-insulin Targeted, anti-insulin Insulin/Polyclonal 
VH281Tg/ Vκ125ki Non-targeted, non-insulin-specific Targeted, anti-insulin Non-insulin/Polyclonal 
125Tg Non-targeted, anti-insulin Non-targeted, anti-insulin Insulin-restricted 
IgHELMD4Tg Non-targeted, anti-HEL Non-targeted, anti-HEL Hen Egg Lysozyme-restricted 
HEL: Hen Egg Lysozyme 
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Anti-insulin B cells make up the majority (95-98%) of the mature repertoire, yet anti-
insulin Abs are a minor fraction of the total circulating Ab; rather, the bulk of circulating 
Abs are derived from the small (2-5%) population of endogenous B cells that do not 
express the anti-insulin Tgs (160). 
 
Evidence for Immature B Cell Anergy 
It was shown in 1980 that culture of flow cytometry-purified IgM- cells with anti-
IgM impaired the ability of the cells to differentiate to become Ab-forming cells in vitro, 
thus providing evidence that functional silencing triggered through BCR stimulation may 
begin early during B cell development (149).  Immature Ars/A1 B cells which harbor an 
anti-arsonate BCR which also recognize self Ags show impaired Ca2+ mobilization in the 
presence of autoAg (13), and show impaired Ca2+ mobilization and homing following 
stromal cell-derived factor-1 (SDF-1) stimulation, which is SHIP-dependent (22).  Much 
of the underlying mechanism that maintains anergy, as well as the ultimate functional 
consequences that occur in anergic immature B cells are still poorly understood.  Work 
presented in Chapter II seeks to further address this important question. 
 
The Discovery of Receptor Editing 
During B cell development, an IgL is rearranged, and if it does not pair well or 
produces an autoreactive specificity when paired with the IgH, a new IgL is rearranged 
which can replace the initial IgL in a process called receptor editing.  The first evidence 
for IgL receptor editing involved the observation by several groups that secondary IgL 
rearrangements were present in B cell lines (53, 88, 96).  This process was shown to be 
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stimulated by anti-BCR Ab, consistent with a mechanism for altering autoreactive 
specificities (96).  It was observed in B cell Tg mouse models that allelic exclusion of the 
Tg IgL was not tightly conserved, again hinting at the potential for a new mechanism of 
tolerance (158, 165).   
Deletion was found to be the predominant tolerance mechanism in autoreactive B 
cells which possessed a non-targeted IgL Tg and recognized highly crosslinking autoAgs 
(71, 128, 130).  In 1993, it was shown that a small fraction of the B cells escaped deletion 
by rearranging an endogenous (non-autoreactive) IgL, and thus demonstrated that such 
Ags could induce receptor editing in a physiologically relevant setting (61, 152, 187).  
The use of such non-Ig-targeted BCR Tg models however does not allow direct study of 
receptor editing as it would normally proceed, because the IgL Tg is randomly integrated 
into the genome, and thus is not subject to replacement attempts occurring at the IgL loci.   
Later work with Ig-targeted BCR Tg models, which represent a much more 
physiologically relevant model for the study of receptor editing, indicated that anti-MHC 
class I or anti-HEL B cells were predominantly censored through receptor editing 
following membrane-bound cognate Ag encounter, and that clonal deletion only occurred 
when receptor editing was not possible, due to RAG-1 deficiency or deletion of the Jκ 
region, both of which are required for novel light chain rearrangements to occur (68, 76).  
Studies show that ~25% of mature B cells in the human polyclonal repertoire show 
evidence of secondary IgL rearrangement, which suggests that IgL receptor editing plays 
an important role in shaping the mature B cell repertoire (31).   
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The Mechanism of Receptor Editing 
In humans, many developing B cell specificities are autoreactive (193).  The 
ability to “edit” an autoreactive BCR to an innocuous specificity therefore represents a 
key salvage pathway that can rescue cells otherwise destined for anergy or deletion.  
Receptor editing is a critical tolerance mechanism that acts during B cell development in 
the bone marrow, and can be stimulated by Ag encounter (61, 152, 187).  RAG proteins 
bind recombination signal sequences (RSS) in DNA to induce double strand breaks to 
mediate DNA recombination (114).  During B cell development, faulty pairing of the IgH 
with the newly rearranged IgL (38, 54), or pairing that produces an autoreactive 
specificity can induce continued RAG expression and rearrangement of a new IgL (61, 
152, 187).  This second IgL then pairs with the existing IgH to form a BCR that will have 
an altered specificity.  Receptor editing involves either inversion or deletion of the DNA 
that codes for the initial IgL rearrangement to ablate its expression, and a second VL and 
JL gene segment are joined to create an IgL with a new specificity.  Deletion of the κ 
constant region (Cκ) can occur if a RSS near the κ  joining region (Jκ)-Cκ intron or at the 
3’ end of a non-rearranged variable region of κ IgL (Vκ) gene recombines with the 
recombination sequence (RS, mice) (46) or the κ-deleting element (humans). 
The work in Chapter IV will focus exclusively on IgL receptor editing, however 
receptor editing is not restricted to the IgL locus, or to B lymphocytes.  Replacement of 
IgH can occur (88, 156), however the ability of Ag to stimulate the BCR to directly 
induce receptor editing is predominantly affiliated with IgL replacement, as enhanced N 
nucleotide addition seen in edited IgHs indicates that editing is initiated prior to IgL 
rearrangement and pairing to result in surface expression of the mature BCR (30, 33, 
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181).  Rearrangement of a second VH to an additional JH is also impaired by the removal 
of intervening DH segments during the initial VH-DH-JH rearrangement; direct VH-JH 
rearrangement violates the 12/23 base pair rule, thus cryptic heptamer RSSs are necessary 
for additional rearrangements to proceed (129).  A high frequency of IgH replacement 
was observed in an anti-DNA transgenic model, in which the pairing of the 3H9 IgH with 
~60% of the available IgLs produces an anti-DNA specificity (79).  It is more likely that 
these IgH editing events are enriched in the mature B cell pool of mice that possess a 
highly autoreactive IgH, and are present due to a selection bias, rather than an actively 
stimulated process.  Although not likely triggered directly by BCR:Ag engagement, this 
process influences the mature repertoire, as 5-12% of human B cells appear to have 
undergone IgH replacement (208). 
It has been observed that secondary rearrangements can occur at the T cell 
receptor (TCR) α or δ loci following TCR engagement (110, 116, 192), which are akin to 
the IgL loci of B cells.  T cells may undergo receptor editing to eliminate autoreactive 
specificities, but they may also edit the TCR to generate sufficient MHC recognition, as 
blocking interactions with MHC via Abs results in RAG re-expression (20). 
 
Hallmarks of Receptor Editing 
Edited B cells can easily be identified in the restricted repertoires of mice 
possessing Ig Tgs with known Ag specificities by detecting a loss of binding to the 
specific Ag.  Studies of such models have identified a correlation between B cells which 
have undergone receptor editing and increased usage of distal Jκs (Jκ4 or Jκ5), whereas 
those which have not undergone receptor editing preferentially rearrange Vκs to upstream 
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Jκs (152, 196).  An increased percentage of B cells expressing λ IgL (Igλ) is also 
indicative of receptor editing (184), as only ~5% of B cells from a normal murine 
repertoire express Igλ (184).  In the polyclonal repertoire of mice, 47% of Igλ-expressing 
B cells show RS rearrangements which inactivate κ IgL (Igκ) (157).  Thus, enhanced 
usage of distal Jκ segments and increased Igλ usage can be used as indirect evidence for 
the presence of receptor editing in a polyclonal repertoire.   
Enhanced RAG expression is observed in H-2Kk,b (MHC class I)-specific B cells 
isolated from H-2Kk mice compared with H-2Kd mice (187), as well as in IgHELMD4Tg 
B cells initiating receptor editing in response to HEL encounter (52).  B cells undergoing 
editing are delayed at least two hours at the pre-BII stage and show increased RAG levels 
compared to non-editing B cells (31).  The increased time spent in the editing-competent 
pre-B cell compartment results in an observable increase in pre-B cells via flow 
cytometry analysis, such that in Ig Tg models, the percentage of pre-B cells is increased 
when autoAg is present, compared with a virtually undetectable population when the 
autoAg is absent (145). 
Receptor editing temporarily, and sometimes permanently, violates the principle 
of allelic exclusion (61), which normally ensures monospecificity of a B cell (146).  
Allelic inclusion sometimes occurs in edited B cells, in which expression of a secondary 
IgL, termed an “editor”, is co-expressed with the initial autoreactive IgL (61, 100).  The 
editor may preferentially compete for IgH binding and therefore surface expression over 
the autoreactive IgL (61), or both IgLs may be expressed on the surface of the cell and 
the editor may function to “dilute out” the autoreactivity intrinsic to the autoreactive IgL 
(100). 
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BCR Transgenic Models of B Cell Receptor Editing 
Receptor editing occurs upon engagement of the BCR with membrane-bound 
Ags, such as membrane-bound HEL, MHC class I, DNA, phosphatidylserine, and type 
IV collagen (34, 61, 93, 97, 187, 189, 207).  The soluble Ag, HEL, was also shown to 
promote receptor editing, showing that Ags that did not strongly cross-link the BCR 
could also induce this process (76, 189).  However, the IgHELMD4Tg BCR binds HEL 
with high affinity (5 x 1010 M-1) (11, 94); thus the 125Tg BCR model allows assessment 
of lower affinity interactions (8 x 106 M-1) (172) and their effects on central tolerance.  
The non-targeted 125Tg model presents the same limitations of other non-Ig-targeted 
models, thus in Chapter IV we develop a new model in which the anti-insulin Vκ125 is 
targeted to the Vκ locus, to facilitate physiologic study of whether insulin can elicit 
receptor editing. 
 
Receptor Editing Enhances Autoreactivity in an Autoimmune Strain 
Receptor editing is a mechanism for abrogating autoreactivity, but it has also been 
implicated in increasing autoreactivity (200).  High-affinity Ab specificities were 
generated from low-affinity precursors through receptor editing on the NZB/NZW 
background, which is a SLE disease model (200).  In a non-autoimmune prone strain, the 
same B cells were targeted for anergy, rather than receptor editing (200).   
It is believed that the slow rate of Igλ rearrangement helps to maintain allelic 
exclusion (154).  Allelic exclusion is not absolute, as demonstrated by B cells that 
express dual IgLs on the surface of the cell, termed “editors” (84, 98).  The purpose of the 
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non-autoreactive IgL presumably “dilutes out” the autoreactive IgL (98).  B cells 
expressing the autoreactive Igλ and the “editor” Igκ are shunted into the marginal zone, 
which is known to preferentially harbor autoreactive B cells (98).  This may prevent the 
participation of autoreactive cells in active immune responses by physically sequestering 
them away from the T cell zone (100).  This sequestration is defective in MRL/lpr mice, 
another SLE model, which may help to explain the disease activity in these mice (99). 
 
Multiple Factors Influence the Type of Tolerance Induced 
The affinity and avidity of the BCR interaction with Ag influences the method of 
B cell tolerance employed.  Strong high-avidity or high-affinity BCR:Ag interactions 
favor deletion, whereas weak interactions elicit receptor editing or anergy (33, 50, 71, 
128, 129, 130, 189).  Anti-ssDNA B cells are anergic, whereas anti-dsDNA B cells 
undergo receptor editing on a non-autoimmune disease-prone mouse strain (198).  
Enhanced strength and avidity of the BCR interaction with autoAg likely elicits increased 
intracellular Ca2+ changes, and increased intracellular Ca2+ is associated with increased 
RAG induction (119).  Stimulation of immature B cells with Ca2+ ionophores, such as 
ionomycin, induces receptor editing, but stimulation with higher doses of ionomycin 
(1μM) triggered apoptosis rather than receptor editing (14), again suggesting that 
enhanced signaling strength alters the tolerance mechanism employed. 
The developmental state of the B cell, as well as the anatomical location in which 
the cell encounters Ag also influences the type of tolerance induction.  BCR crosslinking 
of T1 B cells results in apoptosis (deletion), whereas T2 B cells are stimulated to up-
regulate activation markers and proliferate, showing that the timing of Ag encounter 
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during development drastically alters the response of the B cell (148).  Anti-MHC class I 
Tg B cells that initially encounter Ag in the periphery undergo deletion, whereas those 
encountering Ag during development in the bone marrow undergo receptor editing (187). 
Transitional B cells cultured in the presence of whole bone marrow are protected from 
apoptosis, whereas those cultured in the presence of whole spleen still undergo deletion, 
suggesting that the bone marrow microenvironment protects against deletion and instead 
stimulates receptor editing, whereas the same autoreactive signal encountered in the 
spleen induces cell death (168).   
In contrast to data generated with a conventional Tg model, studies using an anti-
MHC class I Tg targeted to the Igκ locus suggest that receptor editing, rather than 
deletion, is the main mechanism through which tolerance is maintained for this 
membrane-bound Ag (68).  Autoreactive anti-MHC class I and anti-DNA BCR Tgs 
induce receptor editing on a RAG-competent background, but they stimulate clonal 
deletion on a RAG-deficient background to result in the absence of peripheral B cells, 
demonstrating that deletion may be initiated if receptor editing fails (182, 198).  The 
presence of a bcl-2 survival gene spares autoreactive cells from undergoing deletion, but 
anergic programming still remains intact, suggesting that anergy can serve as an 
additional safety mechanism, should deletion fail (71).   
Receptor editing can act as a salvage pathway for autoreactive B cells, however if 
a satisfactory BCR is not generated during a finite period of time, the cell will likely 
undergo anergy or deletion (31).  B cells can likely undergo 2-3 Igκ rearrangement 
attempts before initiating Igλ rearrangement, based on experiments using Igκ-null (Igκ 
enhancer-deleted) mice (7).  The length of time during which the B cells can edit their 
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receptors during development, and potentially the alternative forms of tolerance 
employed depend on the strength and nature of the B cell interaction with Ag (73).  
Taken together, these studies suggest that deletion is a last resort, which initiates when 
other forms of tolerance fail to adequately censor the autoreactive cell. 
 
Research Goals 
The goal of this research is to elucidate how receptor editing and anergy play a 
role in maintaining tolerance in the developing B cell compartment among insulin-
reactive B cells.  Insulin is a key autoAg in T1D (140) and possesses unique antigenic 
features to other well-studied autoAgs such as DNA.  BCR Tg models that exclude or 
allow tolerance through receptor editing are utilized to explore how various tolerance 
mechanisms act on developing anti-insulin B cells. 
 Anergy is known to function in the periphery to silence mature anti-insulin B 
cells, but the ontogeny of this critical process has not been identified.  Chapter II sought 
to ascertain whether developing B cells are functionally silenced following insulin 
encounter, and to what extent they may be impaired.  This was accomplished by 
analyzing functional responses in immature B cells which are known to be impaired in 
mature, anergic B cells.  Immediate and downstream responses of naïve immature B cells 
following activation were compared with those of cells which had encountered insulin, 
thus allowing specific isolation of autoAg influence on the functional state of the cells.  
Study of replacement of the insulin specificity through receptor editing was impaired in 
this model, as the BCR Tg (125Tg) was non-Ig-targeted. 
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 The role that receptor editing plays in establishing tolerance in a polyclonal 
repertoire has not been well characterized.  Work highlighted in Chapter III thus attempts 
to provide evidence that insulin can drive this process in vivo.  Anti-insulin B cells are 
readily detected in the periphery of VH125Tg NOD mice, in which endogenous IgLs pair 
with the anti-insulin VH125 to produce a polyclonal repertoire.  This same population is 
not found in VH125Tg C57BL/6 mice, which do not develop type T1D.  One potential 
explanation for this finding is that receptor editing effectively replaces the anti-insulin 
specificities that emerge in the non-autoimmune strain, but fails to fully abrogate such 
specificities in the autoimmune prone strain, perhaps due to incomplete tolerance 
induction. 
 The anti-insulin Vκ125 is not targeted to the Igκ locus in the current anti-insulin-
restricted BCR Tg model used for studies in Chapter II, and the proportion of insulin-
binding B cells generated in VH125Tg mice is very low (Chapter III).  Ablation of 
autoreactivity through receptor editing is therefore difficult to study with current models.  
In Chapter IV, I therefore describe the development and characterization of a new Tg 
model in which the anti-insulin Vκ125 is targeted to the Igκ locus, and is thus subject to 
replacement if receptor editing is stimulated.  These studies identify the role that insulin 
plays in initiating receptor editing, a critical manifestation of B cell tolerance. 
 The body of work presented in this thesis demonstrates a role for multiple arms of 
B cell tolerance in preventing insulin autoimmunity.  The use of different BCR Tg 
models has provided evidence that a hierarchy of tolerance checkpoints function in 
healthy animals to abolish or silence insulin-reactive B cells in the developing repertoire, 
such that if B cells escape receptor editing, anergy serves as a second line of defense 
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against insulin autoreactivity.  Such tolerance redundancy ensures that autoreactive 
specificities do not functionally participate in immune responses.  These studies highlight 
that a protein hormone, which does not substantially cross-link the BCR and is present at 
a low circulating concentration range, can drive multiple forms of tolerance, and further 
characterization of how these checkpoints are dysregulated in autoimmune-prone animals 
will provide critical insight regarding points at which tolerance may be manipulated to 
enhance disease protection. 
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CHAPTER II 
 
INITIATION AND MAINTENANCE OF FUNCTIONAL SILENCING IN 
IMMATURE ANTI-INSULIN B CELLS 
 
Abstract 
Mechanisms of B cell tolerance act during development in the bone marrow and 
periphery to eliminate or restrict autoreactive clones to prevent autoimmune disease.  B 
cells in the spleens of mice that harbor anti-insulin BCR Tgs (125Tg) are maintained in 
an anergic state by endogenous hormone, but it is not clear when and where anergy is 
induced.  An in vitro bone marrow culture system was therefore used to probe whether 
small protein hormones, a critical class of autoAgs, could interact with the BCR to induce 
anergy early during B cell development.  Upon exposure to insulin, 125Tg immature B 
cells show hallmarks of anergy observed in mature spleen B cells, including BCR down-
regulation, impaired proliferation to anti-CD40, and diminished Ca2+ mobilization 
following acute stimulation.  Inhibition of calcineurin also results in reduced immature B 
cell proliferation, suggesting a potential mechanism through which reduced intracellular 
Ca2+ mobilization may be altering cellular proliferation.  Signs of impairment appear 
after short-term exposure to insulin, which are reversible upon Ag withdrawal.  This 
suggests that a high degree of functional elasticity is maintained at this stage, and that 
constant Ag engagement is required to maintain functional inactivation.  These findings 
indicate that tolerance observed in mature, spleen 125Tg B cells is initiated by insulin in 
the developing B cell compartment, and thus highlight an important therapeutic window 
for the prevention of insulin autoimmunity. 
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Introduction 
Preservation of tolerance in developing and mature B cell compartments is critical 
for the prevention of autoimmune disease.  B cells that escape tolerance can generate 
pathogenic Abs to play a direct autoaggressive role, such as in SLE.  They have 
additionally been shown to indirectly mediate disease, such as in T1D, in which they 
likely present autoAgs to autoaggressive T cells (174).  Multiple routes therefore exist 
through which breaches in B cell tolerance can result in autoimmune disease.  B cell 
tolerance is maintained by the mechanisms of anergy, receptor editing, and deletion (61, 
64, 128, 130, 152, 187).  Among these, anergy is known to function in the periphery to 
silence B cells that recognize soluble protein from actively participating in immune 
responses (40, 131, 160).  Anergic B cells are functionally unresponsive to BCR 
stimulation, show impaired proliferation, compete poorly for follicular entry, have a 
reduced lifespan in the periphery, and fail to differentiate into Ab-secreting plasma cells 
(43).  Anergy is a reversible form of tolerance that must be actively maintained by Ag 
availability (60, 63). 
B cells in mice that harbor anti-insulin Tgs (125Tg) recognize endogenously 
circulating insulin and are rendered anergic in the periphery; thus, an Ag that interacts 
with the BCR with moderate affinity (8 x 106 M-1) and possesses limited BCR 
crosslinking potential is capable of eliciting tolerance (160, 172).  This form of anergy is 
characterized by impaired Ca2+ mobilization upon stimulation and is accompanied by 
diminished basal NFATc1 levels and defective NFATc1 translocation to the nucleus (2).  
Mature, anergic anti-insulin B cells show diminished proliferative responses to anti-IgM, 
anti-CD40, and LPS stimulation, produce little circulating Ab, and do not respond to T 
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cell-dependent immunization (1, 160).  Isolation of naïve 125Tg cells is not possible in 
this model, as ablation of endogenous insulin would rapidly result in animal morbidity 
and mortality, due to the essential nature of the hormone.  This considerable roadblock to 
the dissection of insulin-induced B cell tolerance can be overcome using an IL-7-driven 
in vitro culture system (16, 42, 122).  Accordingly, this culture system was employed to 
identify the developmental ontogeny of anergy in anti-insulin B cells and to directly 
dissect how Ag (insulin) governs tolerance in immature B cells. 
While many studies have mechanistically addressed how the anergic state exists 
in mature B cells, the induction of anergy in immature B cells has not been as well 
characterized.  Previous studies in the Ars/A1 model show that autoreactive immature B 
cells maintain elevated basal levels of intracellular Ca2+ and impaired Ca2+ mobilization 
upon anti-IgM stimulation (13).  Immature B cells which have encountered Ag show 
impaired Ca2+ mobilization and homing following stromal cell-derived factor-1 (SDF-1) 
stimulation, which is SHIP-dependent (22).  Whether and how such changes may alter 
additional downstream functions of autoreactive immature B cells, such as proliferation 
are unknown, and the mechanism through which anergy is established in immature B 
cells has not been adequately addressed.  Unlike mature B cells, immature B cell 
engagement with Ag stimulates tolerance, rather than proliferation (133, 195).  To 
identify whether a small protein hormone can induce anergy in immature B cells and to 
further characterize the extent and nature of unresponsiveness, the phenotype and 
function of immature 125Tg B cells cultured with insulin were assessed. 
We show that in vitro-derived anti-insulin immature B cells are naïve and flux 
Ca2+ following acute stimulation with insulin, anti-IgM, and ionomycin, and confirm that 
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they proliferate upon anti-CD40 stimulation.  These responses are reduced in immature B 
cells that chronically engage insulin in vitro, suggesting that they acquire many hallmarks 
of the anergic phenotype observed for mature B cells.  Similar to chronic insulin 
encounter, inhibition of calcineurin reduces the proliferation of 125Tg immature B cells, 
highlighting a potential mechanism through which the observed changes in intracellular 
Ca2+ mobilization may be negatively regulating cell cycle progression.  These data 
suggest that anergic programming is initiated when developing B cells encounter insulin 
and is dynamically regulated by Ag availability.  Insulin-reactive B cells are therefore 
precariously positioned to escape tolerance during physiological fluctuations of insulin 
and facilitate the development of autoimmunity.  These studies highlight key aspects of 
developing B cell tolerance which must be considered to understand and prevent insulin 
autoimmunity. 
 
Materials and Methods 
 
Animals 
The Ig Tg mice used in this study harbor non-targeted anti-insulin Ig Tgs (125Tg) 
or anti-HEL Tgs, IgHELMD4 on C57BL/6 backgrounds as described previously 
(backcrossed >20 generations to C57BL/6) (24, 160).  IgHELMD4Tg mice were 
purchased from the Jackson Laboratory.  All mice were housed under specific pathogen-
free conditions, and all studies were approved by the Institutional Animal Care and Use 
Committee of Vanderbilt University. 
 
 34
Cell Culture 
Bone marrow was eluted from the long bones of 4-6 wk old animals with Hank’s 
balanced salt solution (HBSS) (Invitrogen Life Technologies) + 10% fetal bovine serum 
(FBS) (HyClone).  Red blood cells (RBCs) were lysed and cells were resuspended at 2 x 
106 cells/mL in complete bone marrow culture media [Dulbecco’s modified eagle 
medium (DMEM) + 10% FBS (HyClone) + L-glutamine + HEPES buffer + MEM 
sodium pyruvate + gentamycin + 2 x 10-5 M 2-mercaptoethanol (2-ME) (Invitrogen)] + 
20% J558L supernatant-derived interleukin 7 (IL-7) (IL-7 expressing J558L cell line 
kindly provided by John Cambier, National Jewish Medical and Research Center, 
Denver, CO) or 15 ng/mL human rIL-7 (Peprotech) and cultured for 5 d in a 37oC CO2 
incubator.  FBS contains fg/mL amounts of insulin, which is below the threshold 
necessary to induce any B cell responsiveness (125Tg included) in all assays tested.  To 
remove IL-7 and promote differentiation, 5 d cultures were washed 3 times with HBSS + 
10% FBS and re-suspended at 2 x 106 cells/mL in complete bone marrow culture media 
without IL-7 and were cultured with or without cognate Ag [human insulin, (Sigma, cat. 
# I2643), or HEL, (Sigma)] for 1-3 d (see Fig. 2-2 assay schematic). 
 
Bone Marrow Proliferation Assay 
Bone marrow cells were harvested and grown in bone marrow culture media with 
IL-7 for 5 d as described above.  Upon IL-7 removal, 0, 500, or 5 x 104 ng/mL human 
insulin (Sigma) was added to the culture.  After 1 d, cells were recounted and plated at 2 
x 10–5 cells/well in 96-well, flat-bottom plates (Corning) with the indicated 
concentrations of insulin and anti-CD40 (HM40-3; BD Pharmingen) “stimulation”, in the 
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absence (unless otherwise noted) or presence of 1 μg/mL cyclosporin A (Alexis 
Biochemicals).  In preliminary studies, 0.5 μg/mL anti-CD40 induced maximal immature 
B cell proliferation.  After 1 d, wells were pulsed with 1 μCi of [3H]thymidine (NEN) and 
grown for 1 d, at which point wells were harvested using a semi-automated cell harvester 
(Skatron).  [3H]Thymidine uptake was measured by scintillation counting after 
stimulation.  Results are reported as the mean ± standard deviation (SD) for the average 
of triplicate determinations for each of the number of mice indicated. 
 
Calcium Mobilization Assay 
Bone marrow B cells derived from the in vitro IL-7 culture system described 
above or magnetic-activated cell separation (MACS)-purified CD43-depleted spleen B 
cells from WT, IgHELMD4Tg, and 125Tg mice were suspended in HBSS (Invitrogen 
Life Technologies) and plated on poly-D-lysine-coated glass bottom microwell dishes 
(MatTek Corporation) for 30 min at 37°C.   Cells were loaded with 5 μM of the cell-
permeant Ca2+-sensitive dye Fura 2-AM (Molecular Probes).  Spleen B cells were 
incubated for 30 min at room temperature, and bone marrow B cells were incubated for 
15 min at 37°C, and were then washed in HBSS.  The dishes were mounted on an 
inverted Nikon TE300 microscope enclosed in a humidified plexiglass chamber 
maintained at 37°C.  Images were collected using a 40X/1.3 NA oil immersion Plan 
Fluor objective lens and a side-mounted CoolSNAPHQ camera.  Fluorescence was 
monitored using dual excitation wavelengths (340/380 nm) and a single emission 
wavelength (510 nm).  Fluorescence at 340 nm indicates dye bound to Ca2+, while that at 
380 nm corresponds to free dye.  Basal readings were taken for 45 s prior to stimulation.  
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Cells were stimulated with the indicated concentrations of anti-IgM [F(ab')2 goat anti-
mouse µ-chain, (Jackson ImmunoResearch Labs, Inc.)], ionomycin (Sigma), human 
insulin (Sigma, I2643), or HEL (Sigma) at 37°C for the times indicated.  Metamorph 
imaging software (Universal Imaging) was used for automated collection of images at 
either 2 or 5 s intervals over a 5 min period.  During this time, cells maintained healthy 
morphology.  Average fluorescence measurements of ≥ 30 cells were determined using 
Metamorph software (Fig. 2-5, A-D and F-G).  Data are expressed as the ratio of 
bound/free Fura 2-AM fluorescence intensities.   
Alternatively, 2 x 105 cells were plated per well in 96 well flat bottom black plates 
(Costar) and were resuspended in 100 μL loading buffer (HBSS + 25 μL DMSO + 1 vial 
Fura-2AM dye + 25 μL pluronic acid (Invitrogen) + 1 % FBS + 500 mM HEPES) 
containing the same concentration of insulin that was previously present.  Cells were 
loaded for 30 min at 37oC and were then washed 3X with Wash Buffer (HBSS + 50mM 
HEPES + 1 % FBS).  Cells were resuspended in 100 μL Wash Buffer containing the 
same concentration of insulin that was previously present.  A FlexStation II fluorimeter 
(Molecular Devices) was used to measure triplicate wells (Fig. 2-5E, 2-7, and 2-8).  
Measurements were taken at 5 s intervals over a 5 min period, 50 μL 3X Stimuli were 
added to wells after 45 s of baseline readings were taken. 
 
Flow Cytometry and Antibodies 
Bone marrow cells were washed in 1X PBS containing 5% FBS, 0.02% EDTA, 
and 0.1% sodium azide and stained with the indicated mAb.  Ab reagents were reactive 
with B220 (6B2), IgMa (DS-1), IgMb (AF6-78), CD43 (S7), CD21 (7G6), CD23 (B3B4), 
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AA4.1 (an immature/transitional B cell marker), or 7AAD (BD Pharmingen).  
Streptavidin reagents (Pharmingen) were used to detect biotinylated reagents.  Analysis 
was performed on a FACSCalibur or LSR II flow cytometer (BD Biosciences).  WinMDI 
2.8 software (Dr. J. Trotter, Scripps Institute, San Diego, CA) was used for analysis. 
 
Statistical Analyses 
Two-tailed, expected mean, one sample t tests or two-tailed, two sample, unequal 
variance t tests were used as indicated to determine statistical significance. 
 
Results 
 
A homogenous population of immature anti-insulin B cells is generated using an IL-
7-driven in vitro bone marrow culture system 
 
Pro-B cell proliferation is enhanced by culture with IL-7, while B cells that have 
differentiated beyond this IL-7-responsive stage die, leaving only Ag-naïve B cells which 
subsequently differentiate to express surface BCR (16, 42, 122).  125Tg bone marrow 
cells were therefore cultured with IL-7 for a 5 d period, and B220 and IgM expression 
were assessed using flow cytometry after an additional 2 d IL-7 withdrawal period (Fig. 
2-1).  In freshly isolated bone marrow, ~5-10% of the cells are B220+, which include 
various stages of B cell development (Fig. 2-1A).  However, upon culture and subsequent 
IL-7 withdrawal, 70-80% of the cells recovered are B220+, and > 90% of the B cells are 
IgMa+ (Fig. 2-1, B-C).  B cells generated in vitro phenotypically resemble immature B 
cells, as they are AA4.1+, CD21-, and CD23- throughout the duration of the culture (Fig. 
2-1, D-F).  This culture system therefore generates Ag-naïve immature B cells to permit 
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Figure 2-1.  Immature anti-insulin B cells are generated in vitro using an IL-7-
driven bone marrow culture system.  Flow cytometry identified expression of B220, 
IgM, AA4.1, CD21, and CD23 on freshly isolated bone marrow cells (A), cells cultured 
with IL-7 for 5 d (B), or cells cultured with IL-7 for 5 d, then 2 d in the absence of IL-7 
(C-F).  (A-F) B220+ 7AAD- cells are shown.  The IL-7-driven culture system used to 
generate naïve 125Tg immature B cells is shown in the schematic in Fig. 2-2A.  All data 
are representative of > 8 experiments.  The average ± SD of B220+-gated cells is: (A) Pro 
and pre (B220+ IgMa-): 14.7 ± 10.6 %, immature (B220mid IgMa+): 61.0 ± 10.2 %, mature 
recirculating (B220high IgMa+): 24.4 ± 10.2 %, (B) B220+ IgMa+: 95.3 ± 6.1, (C) B220+ 
IgMa+: 97.9 ± 1.2 %, (D) B220+ AA4.1+: 91.3 ± 2.9 %, (E) B220+ CD21+: 0.03 ± 0.03 %, 
(F) B220+ CD23+: 0.20 ± 0.17 %. 
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Figure 2-2.  Schematic of IL-7-driven culture system and experimental design.  Ag-
naïve immature B cells are generated by culture with IL-7 for 5 d. IL-7 is then withdrawn 
and (A) cells differentiate for an additional 2 d in the absence or presence of Ag, after 
which flow cytometry analysis or Ca2+ mobilization assays are performed (Fig. 2-3, 2-5, 
and 2-6), or (B) cells differentiated in the absence or presence of insulin for 1 d, at which 
point cells are stimulated with anti-CD40 in the presence or absence of insulin for 1 d.  
Cells are then pulsed with [3H]thymidine for 1 d, and harvested on d8, and [3H]thymidine 
incorporation (counts per minute) is measured (Fig. 2-4, 2-7, and 2-8).  
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investigation of how insulin modulates tolerance.  Subsequent assays were performed 
using IL-7-generated immature B cells, as outlined in Figure 2-2. 
 
Immature anti-insulin B cells down-regulate B cell receptor surface expression upon 
interaction with cognate antigen 
 
 One hallmark of anergy in mature B cells is down-regulation of BCR surface 
expression (64).  To identify whether anti-insulin 125Tg immature B cells (which are 
devoid of IgD) down-regulate the BCR upon encounter with insulin, immature 125Tg B 
cells were generated using the in vitro culture system described (Fig. 2-2A).  After IL-7 
withdrawal, 125Tg cells were cultured in the absence or presence of human or beef 
insulin, for which the 125Tg BCR has an affinity of 3 x 108 M-1 or 3 x 106 M-1, 
respectively (172), and the relative level of IgM expressed on the surface was measured 
using flow cytometry.  As indicated in Figure 2-3A, immature anti-insulin 125Tg B cells 
(white bars) show progressive down-regulation of surface BCR, with increasing Ag 
concentration leading to increased IgM down-regulation.  This is BCR-specific and 
independent of biologic functions of the hormone, as anti-HEL “MD-4” (IgHELMD4Tg) 
immature B cells (black bars) cultured with insulin show no decrease in surface IgM.  A 
similar reduction in surface Ig is observed in anti-HEL immature B cells cultured with 
HEL (data not shown).  Culture of 125Tg immature B cells with beef insulin (gray bars) 
produced levels of IgM downregulation comparable to those observed following culture 
with human insulin (white bars), suggesting that the lower affinity interaction of beef 
insulin is also sufficient to drive this process (Fig. 2-3B).  Importantly, differentiation of 
125Tg B cells to the immature B cell stage is not inhibited by the presence of insulin, as 
the percentage of IgMa+ cells was unaffected (data not shown). 
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Figure 2-3.  Immature anti-insulin B cells down-regulate surface IgM expression 
upon insulin encounter in vitro and do not undergo clonal deletion.  (A-B) Flow 
cytometry to show IgM expression levels.  The IgM mean fluorescence intensity (MFI) of 
cells cultured in the absence of Ag was normalized to 100% and relative IgM expression 
was determined for cells cultured with insulin (ex. 50 ng/mL insulin IgM MFI ÷ 0 ng/mL 
insulin IgM MFI x 100% = relative IgM expression).  (A) Cells were cultured with 
human insulin.  The average of 3 (IgHELMD4Tg, black) or 15 (125Tg, white) 
experiments is shown ± SD, (B) The average of 4 mice ± SD is shown, human insulin, 
white bars; beef insulin, grey bars.  (C) Relative cell recovery in bone marrow culture 
was calculated to minimize experimental differences in IL-7 stimulatory potential by 
dividing the human insulin-cultured cell % recovery by the % recovery of cells cultured 
without insulin in the same experiment, % recovery was calculated by dividing the end 
cell number by the input cell number.  The average of 18 experiments ± SD is shown.  
(D) Histograms showing percentages of B220+ cells present at the end of the culture 
assessed using flow cytometry.  The average of 17 experiments ± SD is shown.  Ag-naïve 
immature B cells are generated as in Fig. 2-2A and cells are harvested after culture with 0 
– 5 x 104 ng/mL insulin.  * p < 0.05, ** p < 0.005, as calculated by a two-tailed, expected 
mean, one sample t test. 
 42
 IgM surface downregulation, a phenotype of anergic B cells (64), is observed in 
125Tg immature B cells cultured with insulin, indicating that B cell tolerance may be 
induced by this protein hormone.  In addition to anergy, receptor editing or clonal 
deletion are also potential tolerance outcomes (61, 64, 128, 130, 152, 187).  In the 125Tg 
model, the Ig Tgs are not targeted to the Ig loci, thus censoring of the autoreactive 
receptor through receptor editing cannot proceed in a physiological manner; however, 
deletion is possible.  To establish whether clonal deletion was being triggered, total cell 
numbers were counted upon culture with insulin and the relative cell recovery was 
determined based on input cell numbers.  Neither the relative cell recovery nor the 
percentage of B cells present upon culture with insulin was altered (Fig. 2-3, C-D); thus, 
encounter even with high concentrations of insulin does not induce deletion, as occurs 
with BCR crosslinking by anti-IgM stimulation (not shown).  These findings demonstrate 
that the principal outcome of BCR engagement with insulin is to decrease surface BCR 
expression in 125Tg immature B cells, a phenotype typical of mature B cells that are 
rendered anergic. 
 
Cognate antigen encounter impairs CD40-induced proliferation of immature anti-
insulin B cells 
 
Whereas BCR crosslinking does not stimulate proliferation of immature B cells 
(32, 201), other types of stimulation can drive this process.  Simultaneous co-stimulation 
of the BCR and CD40 inhibits immature B cell apoptosis and allows immature B cells to 
overcome the block to cell cycle entry and are capable of proliferating (164, 169), and 
CD40 stimulation alone is sufficient to drive immature B cell proliferation (23).  These 
findings suggest that T cell help signals can override negative signals stemming from 
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BCR signaling alone and thus may help to maintain relevant specificities in the repertoire 
for effective pathogen clearance.   
125Tg immature B cells that encounter insulin show IgM down-regulation (Fig. 
2-3), a phenotype consistent with cells inducing anergy (64).  Anti-CD40 stimulation 
(which emulates T cell help), bypasses the BCR to induce immature and mature B cell 
proliferation (23), but this response is impaired when mature anti-insulin B cells are 
exposed to insulin in vivo (1).  To identify whether a similar diminished responsiveness is 
evoked by Ag engagement of immature B cells, Ag-naïve immature B cells were 
generated using IL-7 culture, and were subsequently cultured for 1 d with or without 
insulin.  Cells were then stimulated with anti-CD40 for an additional 2 d, during which 
the initial insulin concentration indicated remained present (see Fig. 2-2B for 
experimental design schematic).  As shown in Figure 2-4, [3H]thymidine uptake indicated 
that proliferation of 125Tg, but not control IgHELMD4Tg immature B cells was reduced 
~2-3 fold upon stimulation with anti-CD40 in the presence of insulin.  These data suggest 
that even modest concentrations of insulin are capable of downmodulating immature B 
cell proliferation when compared with naïve cells stimulated in the absence of cognate 
Ag.  This interaction is BCR-specific and independent of any hormonal effects, as the 
presence of even the highest dose of insulin does not alter IgHELMD4Tg immature B 
cell proliferative responses. 
 
Calcium mobilization is impaired in immature B cells upon insulin encounter 
The intracellular Ca2+ concentration in a cell is tightly regulated and can be 
rapidly modulated by various stimuli to produce dynamic changes in a wide array of
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Figure 2-4.  Immature anti-insulin B cells chronically cultured with insulin in vitro 
show impaired proliferation to anti-CD40.  Immature B cell proliferation to anti-CD40 
was assessed.  125Tg (A) or IgHELMD4Tg (B) cells were naïve (white bars) or cultured 
with human insulin (500 ng/mL, grey bars, or 5 x 104 ng/mL, black bars) for 1 d, then 
stimulated with CD40 (x-axis) in the presence of the indicated concentration of insulin.  
[3H]thymidine incorporation (counts per minute) was measured.  Bars represent the 
average of triplicate determinations of 3 animals, error bars represent the SD, * p < 0.03, 
** p < 0.007, as calculated by a two-tailed, two sample/unequal variance t test.  Immature 
B cells were generated as in Fig. 2-2B. 
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cellular processes, and altered Ca2+ homeostasis is associated with lymphocyte anergy 
(67).  The 125Tg BCR interacts with insulin with a lower affinity and does not lead to 
substantial BCR crosslinking compared with other available Tg models of B cell 
tolerance (11, 172).  We therefore tested whether insulin could elicit a sufficiently strong 
signal to evoke Ca2+ flux by measuring Ca2+ mobilization.  Ag-naïve immature 125Tg B 
cells fluxed Ca2+ following acute insulin, but not HEL stimulation (Fig. 2-5A), and small 
responses have been observed with as little as 50 ng/mL insulin stimulation (not shown).  
Naïve IgHELMD4Tg immature B cells mobilized Ca2+ when stimulated with HEL as a 
positive control, but not insulin (Fig. 2-5B).  These data suggest that a small protein 
hormone Ag can interact with the BCR to elicit changes in intracellular Ca2+ 
concentration and confirm that cells generated in vitro are naive.  
The anergic phenotype observed in anti-insulin mature B cells includes an 
impaired ability to mobilize Ca2+ upon acute stimulation with ionomycin and suboptimal 
doses of anti-IgM (2).  To determine whether a similar impairment in Ca2+ mobilization 
exists in immature B cells that have previously encountered insulin, Ag-naïve immature 
125Tg B cells were generated in vitro and were cultured with or without insulin (Fig. 2-
2A).  Cells were then acutely stimulated with insulin, anti-IgM, or ionomycin and 
intracellular Ca2+ mobilization was measured.  Immature 125Tg B cells that have 
previously encountered insulin showed an impaired ability to mobilize Ca2+ upon acute 
stimulation with insulin (Fig. 2-5D) or anti-IgM (Fig. 2-5E), similar to what is observed 
in mature 125Tg spleen B cells (Fig. 2-5C, (15)).  As immature 125Tg B cells cultured 
with insulin downregulate surface IgM, the impaired Ca2+ flux that is observed may be 
due to reduced BCR molecules available for Ag engagement.  Ionomycin was thus used 
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to bypass the BCR and stimulate intracellular Ca2+ mobilization.  125Tg and control 
IgHELMD4Tg naïve immature B cells produced a robust response of equivalent 
magnitude upon stimulation with ionomycin (Fig. 2-5F), which was diminished following 
culture with insulin (Fig. 2-5G).  These findings suggest that immature B cells can be 
rendered unresponsive to BCR or ionomycin stimulation upon prior encounter with a 
small protein such as insulin, which has limited BCR crosslinking potential.  This tolerant 
state mimics the state of altered intracellular Ca2+ homeostasis in mature tolerant anti-
insulin B cells. 
 
Calcineurin inhibition impairs immature B cell proliferation 
Elevation of intracellular Ca2+ levels leads to enhanced calcineurin activity in mature 
lymphocytes, which can result in many downstream biological changes, including cell 
proliferation (67).  To probe whether calcineurin activity affects immature 125Tg B cell 
proliferation, [3H]thymidine uptake of immature B cells grown in the absence of insulin 
and stimulated with anti-CD40 was assayed (as in Fig. 2-2), in the presence or absence of 
cyclosporin A, a calcineurin inhibitor.  As shown in Fig. 2-6, immature B cell 
proliferation to anti-CD40 stimulation was diminished in the presence of cyclosporin A.  
This impairment indicates that calcineurin is required for maximal immature B cell 
proliferation to anti-CD40.  These findings suggest that calcineurin plays a role in 125Tg 
immature B cell proliferation to anti-CD40, and thus provide a potential mechanistic link 
between the diminished Ca2+ mobilization and impaired proliferation observed in 125Tg 
immature B cells which chronically engage insulin. 
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Figure 2-5.  Calcium mobilization is impaired in anti-insulin immature B cells upon 
chronic insulin encounter.  Intracellular Ca2+ mobilization was measured.  Cells were 
loaded with fura 2-AM.  Basal fluorescence readings are taken for 45 s, arrow indicates 
stimulation.  125Tg (A) or IgHELMD4Tg (B) naïve immature B cells (generated as in 
Fig. 2-2A) were stimulated with human insulin (solid line) or HEL (dashed line).  (C) 
Mature, anergic 125Tg spleen cells were stimulated with human insulin. 125Tg naïve 
immature B cells were cultured ± human insulin (0 ng/mL: black solid line, 500 ng/mL: 
dashed black line, 5 x 104 ng/mL: dashed grey line) for 1 d and stimulated with human 
insulin (D), anti-IgM (E), or ionomycin (G).  (F) 125Tg (grey line) or IgHELMD4Tg 
(black line) naïve immature B cells were stimulated with ionomycin.  Data are 
representative of 3 or more experiments. 
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Figure 2-6.  Calcineurin inhibition impairs immature anti-insulin B cell 
proliferation to anti-CD40 stimulation.  Proliferation to anti-CD40 was measured.  
125Tg immature B cells were cultured in the absence of insulin for 1 d, then stimulated 
with CD40 (x-axis) in the absence (white bars) or presence of 1 μg/mL cyclosporin A 
(black bars).  [3H]thymidine incorporation (counts per minute) was measured.  Bars 
represent the average of triplicate determinations of 4 animals, error bars represent the 
SD, * p < 0.021, ** p < 0.0048, as calculated by a two-tailed, two sample/unequal 
variance t test.  Immature B cells were generated as in Fig. 2-2B. 
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Extended exposure of 125Tg immature B cells to insulin is not required to observe 
IgM downregulation, impaired calcium mobilization, or diminished proliferation 
 
In the previous experiments, insulin (if added) was present continuously 
throughout the multi-day culture period.  To determine if signs of tolerance were present 
after short-term culture with insulin, immature anti-insulin (125Tg) B cells were cultured 
for 0.5-5 h with or without insulin after IL-7 withdrawal and 1 d without insulin.  Flow 
cytometry analysis indicated that IgM expression decreased after 0.5 h of culture with 
insulin, and continued to decrease with time (grey and black bars, Fig. 2-7A).  125Tg 
immature B cells also showed impaired Ca2+ mobilization upon acute insulin or anti-IgM 
stimulation following culture with insulin for 3 h (earlier timepoints were not assessed) 
(Fig. 2-7, B-C).  To test whether primary insulin co-exposure with anti-CD40 stimulation 
is sufficient to impair proliferation, Ag-naïve 125Tg immature B cells were cultured for 1 
d in the absence of insulin (Fig. 2-2B).  Anti-CD40 and insulin were then simultaneously 
added and the cells were cultured for an additional 2 d, prior to measuring [3H]thymidine 
uptake.  Proliferation was dampened in cells which had encountered insulin concurrent 
with anti-CD40 stimulation (Fig. 2-7D), suggesting that an extended period of “anergic 
reprogramming” prior to anti-CD40 stimulation is not required for insulin to impair 
proliferation. 
 
Maintenance of immature anti-insulin B cell anergy requires continuous antigen 
presence 
 
To identify whether anergy in immature anti-insulin B cells requires continuous 
Ag exposure, 125Tg B cells were cultured with or without insulin (Fig. 2-2A) and 
relative IgM expression (Fig. 2-8A) and Ca2+ mobilization (Fig. 2-8, B-C) were assessed.   
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Figure 2-7.  Functional impairment is observed in anti-insulin B cells after short-
term exposure to insulin.  Naïve immature 125Tg B cells were generated (as in Fig. 2-
2).  (A) Flow cytometric analysis showing relative IgM expression levels on 125Tg cells 
cultured for 0.5-5 h in the presence of human insulin, as calculated in Fig 2-3A.  The 
average of 7 animals ± SD is shown, * p < 0.01, ** p < 0.007, as calculated by a two-
tailed, expected mean, one sample t test.  (B-C) Intracellular Ca2+ mobilization was 
measured in cells cultured for 1 d with no insulin, followed by 0 ng/mL (solid black line), 
500 ng/mL (dashed grey line), or 5 x 104 ng/mL human insulin (dashed black line) for 3 h 
and stimulated with human insulin (B) or anti-IgM (C).  Data are representative of > 5 
animals.  (D) [3H]thymidine incorporation (counts per minute) was measured.  Following 
culture without insulin for 1 d, anti-CD40 (x-axis) and 0 ng/mL (white bars), 500 ng/mL 
(grey bars), or 5 x 104 ng/mL (black bars) human insulin were added simultaneously and 
the cells were cultured for an additional 2 d.  The average of triplicate values from 3 
animals ± SD is shown, † p < 0.031, ‡ p < 0.001, as calculated by a two-tailed, two 
sample/unequal variance t test. 
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Figure 2-8.  Functional impairment of 125Tg immature B cells is highly reversible.  
125Tg immature B cells were cultured (Fig. 2) with continuous Ag (d1-d2) or Ag was 
withdrawn from the culture (Ag added d1, removed d2), IgM down-regulation, calcium 
mobilization, and proliferation were assessed.  (A) Flow cytometric analysis showing 
relative IgM expression levels, as calculated in Fig 2-3A.  The average of 8 animals ± SD 
is shown.  (B-C) Intracellular Ca2+ mobilization was measured in cells cultured with 0 
ng/mL (solid black line), 500 ng/mL (dashed grey line), or 5 x 104 ng/mL human insulin 
(dashed black line) for 2 d (continuous insulin presence, B), or 1d, followed by antigen 
removal and 1 d additional culture in the absence of insulin (insulin withdrawal, C) and 
stimulated with human insulin.  Data are representative of 4 animals.  (D) [3H]Thymidine 
incorporation (counts per minute) was measured.  500 ng/mL human insulin was absent 
for 3 d (solid white bars), continuously present for 3 d (solid grey bars), or added for 1 d 
and then removed for 2 d (striped grey bars), cells were stimulated with anti-CD40 (x-
axis) for the final 2 d period.  The average of triplicate values ± SD is shown, data are 
representative of 2 animals.  A two-tailed, two sample/unequal variance t test was used to 
calculate significance for all bar graphs, * p < 0.001, ** p < 0.0007. 
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Continuous Ag was present (grey and black solid bars, Fig. 2-8A, or grey and black 
dashed lines, Fig. 2-8B) or Ag was removed (grey and black striped bars, Fig. 2-8A, or 
grey and black dashed lines, Fig. 2-8C) and cells were cultured for an additional day.  
Removal of Ag for 1 d (striped bars) resulted in restoration of relative surface IgM 
expression compared to continuous Ag presence (solid bars, Fig. 2-8A).  Insulin 
withdrawal also restored the ability of cells to mobilize Ca2+ upon acute stimulation with 
insulin (Fig. 2-8C).  Using a similar approach, withdrawal of insulin upon addition of 
anti-CD40 resulted in reversion of the level of proliferation to the levels found in naïve 
cells (Fig. 2-8D).  Together, these data indicate that immature B cells retain a high level 
of functional elasticity, initiating or suppressing the anergic phenotype based on Ag 
availability.   
 
Discussion 
Using IL-7-driven bone marrow culture, we find that naïve immature B cells can be 
generated that mobilize Ca2+ upon insulin stimulation and proliferate upon CD40 
engagement.  However, immature 125Tg B cells exposed to insulin adopt many of the 
tolerant phenotypes observed in mature 125Tg spleen B cells, including surface IgM 
down-regulation, reduced Ca2+ mobilization upon stimulation with insulin, anti-IgM, or 
ionomycin, as well as impaired proliferative responses to anti-CD40 stimulation.  This 
functional impairment is induced in an Ag-specific fashion, and is not due to the 
hormonal activity of insulin.  These findings therefore suggest that a small protein 
hormone, such as insulin, is capable of altering the biological responsiveness of immature 
bone marrow B cells in a way that closely resembles the anergic phenotype observed in 
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mature B cells.  This initial phase of anergy induction likely serves as a critical line of 
defense against autoaggressive B cells present in the developing repertoire.   
 Tonic signaling emanating from BCR surface expression is critical for B cell 
development to proceed (90, 117, 176).  A lack of positive signaling due to BCR down-
regulation induces receptor editing, another arm of developing B cell tolerance (171).  
The 125Tg non-targeted transgenic model is not ideal to study how this process 
physiologically proceeds; therefore a targeted model was generated and studies 
addressing whether receptor editing is involved in maintaining tolerance for insulin are 
described in Chapter IV.  Whether or not frustrated editing attempts are made, anergy is 
still induced in 125Tg immature B cells to effectively censor self-reactivity.  We 
hypothesize that the IgM down-regulation seen in 125Tg immature B cells cultured with 
insulin may similarly diminish the amount of positive signaling generated, which may in 
part account for the reduced Ca2+ mobilization observed.  Culture with 500 ng/mL insulin 
results in a modest reduction of surface IgM (Fig. 2-3A), yet results in more substantial 
impairment in Ca2+ mobilization (Fig. 2-5, D-E).  Thus, even a modest reduction in 
surface IgM expression may correlate with biologically relevant functional outcomes, and 
highlights the exquisite sensitivity that immature B cells possess to detect cognate Ag.  
Additionally, ionomycin responsiveness, which bypasses the BCR, is also impaired (Fig. 
2-5G), supporting that functional impairment involves changes in the way cells manage 
intracellular Ca2+ increases, and is not solely due to reduced Ag engagement of surface 
BCR. 
Intracellular Ca2+ increases up-regulate calcineurin activity, which 
dephosphorylates NFAT to promote its nuclear translocation to induce proliferation in 
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mature lymphocytes (67).  Calcineurin inhibition results in decreased 125Tg immature B 
cell proliferation to anti-CD40 (Fig. 2-6).  We therefore propose a model in which 
immature 125Tg B cells chronically engaging insulin enter an impaired state by down-
regulating the BCR.  This limits the magnitude of intracellular Ca2+ increases derived 
from tonic BCR signaling, to diminish calcineurin activity.  The magnitude of cell 
proliferation to anti-CD40 stimulation is therefore impaired, due to this reduction in tonic 
signaling.  This may be achieved by reducing nuclear translocation of NFAT, a well-
known target of calcineurin (67), which occurs in mature, anergic 125Tg B cells (2).  
Alternatively, calcineurin has also been shown to dephosphorylate cell cycle proteins, 
such as CDK4 (10), and calcineurin inhibition inactivates CDK2 in late G1 or S phase 
due to p27 accumulation (82), thus highlighting another potential method of cell cycle 
control.   
BCR downregulation and impaired Ca2+ mobilization are observed after 3 h 
insulin exposure (Fig. 2-7, A-C), and immature B cells simultaneously exposed to insulin 
and anti-CD40 show impaired proliferative responses (Fig. 2-7D).  Any transcriptional 
changes required to suppress proliferation appear to be able to occur concomitantly with 
those that support proliferation to result in a dominant anti-proliferative effect.  These 
findings raise the possibility that the anergic state observed does not require substantial 
prior genetic reprogramming.  Ca2+ is required for cell cycle progression (82); thus it 
seems likely that the impaired Ca2+ mobilization observed is linked to the downstream 
reduction in proliferative responses.  Immature anti-insulin B cell anergy is reversible 
upon Ag withdrawal, as BCR surface expression, Ca2+ mobilization, and proliferation to 
anti-CD40 stimulation return to levels observed for naïve cells (Fig. 2-8, A-D), which is 
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also consistent with the highly sensitive and responsive qualities of intracellular Ca2+ 
mobilization. 
The anti-insulin Ig Tg model (125Tg) enables the study of how tolerance is 
initiated and maintained for physiologically relevant proteins such as hormones which 
have low-valency interactions with the BCR, and highlights a different form of anergy 
induction from what is observed in other models of tolerance.  In vitro culture with IL-7 
generates naïve immature B cells not accessible in vivo.  The affinity of the 125Tg BCR 
for human insulin (used in in vitro assays due to high purity) is 3 x 108 M-1 (172), which 
contrasts with the more than 100-fold higher affinity of IgHELMD4Tg for HEL (5 x 1010, 
(11)), the only other low-valency model of B cell anergy.  Comparable IgM surface 
down-regulation is observed following culture with beef insulin (Fig. 2-3B) which has a 
lower affinity (3 x 106 M-1) than rodent insulin (8 x 106 M-1) (172).  If the reduction in 
positive signaling from surface BCR is responsible for the tolerance phenotype observed 
in immature 125Tg B cells cultured with human insulin, this suggests lower affinity 
species of insulin will also elicit anergy.  The concentration of insulin present in vitro (50 
– 5 x 104 ng/mL) is higher than the circulating concentration of insulin in vivo (1 ng/mL), 
which can increase 5-10 fold based on physiologic demand (56).  However, BCR 
internalization of insulin in vitro reduces the concentration of Ag available throughout the 
culture duration, whereas insulin homeostasis in vivo is tightly regulated.  The initial 
insulin concentration present is well below the concentration at which insulin forms 
dimers (100 μg/mL) (17).  Immature B cells show a decreased threshold for activation 
through the BCR compared with mature B cells (reviewed in 85), thus it seems plausible 
that endogenous levels of rodent insulin, which are sufficient to occupy virtually all of 
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the surface BCR and induce anergy in mature 125Tg B cells in vivo (160), would be 
capable of inducing anergy in immature B cells as well.  As little as 50 ng/mL insulin can 
mobilize Ca2+ in immature B cells (not shown), consistent with highly sensitive 
biological responses occurring with low concentrations of Ag.   
Insulin is a key autoAg in T1D (206), and its availability in the bloodstream 
fluctuates hourly with physiological responses to increases in blood glucose (56), unlike 
other autoAgs which may be present at more constant levels.  This may therefore 
represent an important consideration in understanding fully how tolerance is maintained 
for protein hormones, as this oscillation may allow a brief window for some autoreactive 
cells to escape into the periphery.  The functionality of tolerance at multiple checkpoints 
is thus likely to be critical for autoimmune disease prevention, particularly with respect to 
this category of autoAgs.  Developing a better understanding of how cells can become 
functionally silenced may aid in the identification of novel therapeutic targets for the 
treatment of autoimmune disease and graft rejection.  The site and stage of tolerance 
induction is important in the consideration of designing novel therapeutics, and these 
studies highlight an important developmental stage for potential therapeutic intervention 
in autoimmune disease. 
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CHAPTER III 
 
INSULIN INDUCES CENTRAL TOLERANCE IN A DEVELOPING 
POLYCLONAL B CELL REPERTOIRE 
 
Abstract 
Loss of immune tolerance in the B cell compartment accompanies many 
autoimmune disorders, including T1D.  Peripheral tolerance for insulin is maintained by 
anergy, however regulation by central tolerance mechanisms has not been assessed.  We 
find that B cells harboring an anti-insulin IgH Tg (VH125Tg) paired with targeted IgL 
Tgs show evidence of receptor editing in vivo.  Insulin-binding B cells develop in bone 
marrow, but not in spleen polyclonal repertoires of VH125Tg C57BL/6 non-autoimmune 
disease-prone mice.  In contrast, T1D-prone VH125Tg NOD mice generate anti-insulin B 
cells in the spleen, which are increased compared with the bone marrow.  VH125Tg 
NOD bone marrow B cells cultured in vitro in the absence of Ag generate an increased 
percentage of insulin-specific B cells compared with VH125Tg C57BL/6 cells.  B cells 
possessing VH125 (compared with non-insulin-specific VH281) paired with endogenous 
IgLs (VH125Tg and VH281Tg, respectively) show increased rag-2 transcript levels, 
consistent with increased receptor editing.  These data suggest that insulin elicits central 
tolerance in developing insulin-specific B cells present in a polyclonal repertoire in vivo, 
which is dysregulated in the T1D-prone NOD strain.  This is compounded by the 
enhanced potential of the NOD IgL repertoire to generate an autoreactive BCR.  
Multifactorial differences may therefore contribute to the development and allowance of 
insulin-specific B cells in the periphery of NOD mice. 
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Introduction 
 Breaches in B cell tolerance precede the development of many autoimmune 
diseases.  Autoreactive B cells can directly mediate tissue damage when they differentiate 
and produce pathogenic autoAbs, such as anti-DNA Abs in SLE, or play an indirect role, 
as suggested for T1D, where B cells capture and present key self Ag to autoaggressive T 
cells (174).  The mechanisms that normally remove autoreactivity include anergy, 
receptor editing, and deletion (61, 64, 128, 130, 152, 187).  The bulk of studies describing 
the role of tolerance mechanisms in B cell development were made possible by Ig Tg 
models, as tracking the fate and function of Ag-specific B cells is facilitated in a 
restricted repertoire.  Using this approach, we have shown that anti-insulin 125Tg B cells 
in the peripheral repertoire are anergic (160).  In addition, the anti-insulin VH transgene 
(VH125Tg) paired with endogenous IgLs generates a detectable population of peripheral 
B cells that bind insulin in autoimmune-prone NOD mice; however similar B cells are not 
found in the periphery of C57BL/6 mice (78, 197).   
The failure to detect insulin-binding B cells in VH125Tg C57BL/6 mice (197) 
raises the possibility that central tolerance may effectively cull these specificities in the 
non-autoimmune strain, either through receptor editing, deletion, or altered peripheral 
survival associated with anergy.  Additionally, it has been previously shown that 
polymorphisms exist in NOD IgLs which are conserved among other autoimmune-prone 
strains and differ from non-autoimmune strains (197).  It therefore seems plausible that 
the IgL repertoire of the NOD strain that pairs with VH125Tg may be better suited to 
generate an insulin-binding BCR.  Whether central tolerance is elicited for insulin, which 
is impaired in NOD mice, and/or whether enhanced generation of insulin-binding B cells 
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is responsible for the presence of these cells in the periphery of NOD mice has not been 
addressed. 
We find that B cells harboring anti-insulin VH125Tg paired with multiple 
targeted IgLs undergo receptor editing and replace the targeted IgL.  Evidence for 
receptor editing in a polyclonal repertoire is also provided in C57BL/6 mice; rag-2, 
required for receptor editing, is increased in VH125Tg compared to non-insulin-binding 
VH281Tg animals, suggesting that an insulin-specific IgH might stimulate receptor 
editing.  Further, insulin-binding B cells are detected in the developing, but not peripheral 
repertoire of VH125Tg C57BL/6 mice in vivo.  This contrasts with T1D-prone VH125Tg 
NOD mice, which positively select for insulin-specific B cells in the periphery from the 
developing repertoire.  An increased frequency of insulin-binding B cells develop in vitro 
in the absence of Ag in VH125Tg NOD mice.  These data suggest that the IgL repertoire 
of NOD mice is more permissive for the generation of insulin-binding B cells when 
VH125 is present, and that flaws in central tolerance may seed autoreactive specificities 
in the repertoire of the autoimmune strain that are normally removed early in 
development.  
 
Materials and Methods 
Animals 
The VH125Tg (anti-insulin), VH281Tg (non-insulin specific), and 125Tg 
(insulin-binding) mice used in this study harbor non-targeted Tgs on C57BL/6 or NOD 
backgrounds as described previously (81, 160, 186).  IgHELMD4Tg mice that harbor 
anti-HEL BCRs (24) were purchased from The Jackson Laboratory.  Previously 
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described Vκ1ki (Vκ1-110-Jκ1), Vκ4ki (Vκ4-81/Jκ4), and Vκ8ki (Vκ8-19/Jκ5) mice 
were kindly provided by Dr. Martin Weigert (University of Chicago) (34, 150).  Vκ1ki, 
Vκ4ki, or Vκ8ki mice were intercrossed with VH125Tg animals to generate 
VH125Tg/Vκ1ki, VH125Tg/Vκ4ki, or VH125Tg/Vκ8ki mice, respectively.  All data are 
derived from lines that have been backcrossed >20 generations to C57BL/6 or NOD, and 
which are hemizygous for all Tgs indicated.  All mice were housed under specific 
pathogen-free (C57BL/6) or sterile housing (NOD) conditions, and all studies were 
approved by the Institutional Animal Care and Use Committee of Vanderbilt University. 
 
Flow Cytometry 
Flow cytometry analysis was performed using a FACSCalibur flow cytometer or 
LSRII (BD Biosciences).  Ab reagents (BD Pharmingen): B220 (6B2), IgMa (DS-1), 
IgMb (AF6-78), and CD43 (S7).  Insulin (Sigma) was biotinylated at pH 8.0 in bicine 
buffer using biotin N-hydroxysuccinimide ester (Sigma) and detected with streptavidin 
(BD Pharmingen).  WinMDI 2.8 software (Dr. J. Trotter, Scripps Institute, San Diego, 
CA) was used for analysis. 
 
Determination of Vκ Usage 
Spleen cells from 6-10 individual animals were positively selected with IgMa-
biotin (BD Pharmingen, DS-1) and streptavidin magnetic beads (Miltenyi) through 
autoMACS sorting (Miltenyi) to >95% IgMa+ cell purity.  RNA was isolated using the Tri 
Reagent manufacturer’s instructions (Molecular Research Center).  First strand cDNA 
was generated from total RNA using Superscript II RT (Invitrogen) and 0.67 μg oligo-dT 
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primer (Amersham Biosciences) in a standard protocol.  Vκ sequences were amplified 
from first strand cDNA using the following primers: murine Cκ primer - 5’GGA TAC 
AGT TGG TGC AGC ATC and murine VκA - 5’ATT GTK MTS ACM CAR TCT CCA, 
where K=G or T, M=A or C, S=C or G, R=A or G.  Vκ sequences were amplified using 
AmpliTAQ DNA Polymerase (2U/reaction) (Applied Biosystems), 200 nM dNTP, 1.25 
mM MgCl2, 13.35 mM Cκ primer and VκA primer; 94oC/1 min, 42oC/1 min, and 72oC/1 
min for 40 cycles.  PCR product was ligated into pGEM-T Easy Vector System I plasmid 
(Promega).  Clones were sequenced using an Applied Biosystems 3730xl DNA Analyzer 
(Vanderbilt-Ingram Cancer Center, Nashville, TN).  Vκ gene segment sequence 
alignments were assigned using the ImMunoGeneTics (IMGT) database 
(www.imgt.cines.fr:8104/).  Individual clones are each derived from independent pools of 
RNA.   
 
Real-Time Polymerase Chain Reaction (PCR) 
RNA was prepared from freshly isolated bone marrow from VH125Tg or 
VH281Tg C57BL/6 mice using Tri Reagent according to the manufacturer’s instructions 
(Molecular Research Center).  First strand cDNA was generated as for Vκ usage analysis 
(above).  Resultant cDNA template was used in real-time PCR with the following primers 
to amplify rag-2 and cd19 (55oC annealing temperature): rag-2 forward (FWD): 
5’CACATCCACAAGCAGGAAGTACAC, rag-2 reverse (REV): 
5’GGTTCAGGGACATCTCCTACTAAG, cd19 FWD: 
5’GTGGCCAAAGCGTCCATC, cd19 REV: 5’GAGAGCACATTCCCGTAC, rag-2 
transcript levels were normalized to cd19. 
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Cell Isolation and Culture 
Bone marrow was eluted from femurs, tibias, and humeri of 4-6 week old animals 
with HBSS (Invitrogen) + 10% FBS (HyClone).  RBCs were lysed and cells were stained 
for flow cytometry analysis or resuspended at 2 x 106 cells/mL in DMEM + 10% FBS + 
L-glutamine + HEPES + MEM sodium pyruvate + gentamycin + 2 x 10-5 M 2-ME 
(Invitrogen) + 20 % J558L supernatant-derived IL-7 or 15 ng/mL human rIL-7 
(Peprotech) and cultured for 5 d in a 37 oC CO2 incubator (IL-7 expressing J558L cell 
line kindly provided by John Cambier, National Jewish Medical and Research Center, 
Denver, CO).  To remove IL-7, 5 d cultures were washed with HBSS + 10% FBS and 
were resuspended at 2 x 106 cells/mL in culture media without IL-7 and grown for an 
additional 2 d, at which point cells were harvested and stained for flow cytometry 
analysis.  Spleens were harvested and RBCs were lysed using Tris-NH4Cl.  Cells were 
resuspended and stained for flow cytometry. 
 
Statistical Analyses 
Two-tailed, two sample, unequal variance t tests were used as indicated to 
determine statistical significance. 
 
Results 
 
Transgene-associated developmental acceleration through the IgM- stage is not 
observed in VH125Tg/Vκki B cells 
 
Non-Ig-targeted BCR Tg models (e.g. 125Tg) do not permit the study of how 
receptor editing physiologically proceeds, as this process is directed at the IgL loci.  To 
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directly test whether B cells harboring anti-insulin VH125 undergo receptor editing, 
VH125Tg mice were intercrossed with mice harboring Igκ-targeted Vκ transgenes to 
generate three lines, VH125Tg/Vκ1ki, VH125Tg/Vκ4ki, and VH125Tg/Vκ8ki.  Vκ1ki, 
Vκ4ki, and Vκ8ki Tgs are useful in this regard because their ability to undergo receptor 
editing when paired with an anti-DNA IgH has been well examined in elegant studies on 
anti-DNA specific BCRs (150, 199).  In addition, a prior study in NOD found that 
VH125 can pair with closely related Vκ1-110 (Vκ1ki) and Vκ4-81 (Vκ4ki) genes (197).  
For ease, Tg models utilized are described in Table 3-1.   
The pre-B cell compartment of mice that harbor Ig Tgs is greatly reduced in the 
absence of autoAg compared with WT mice; however this compartment is restored if the 
autoAg is present, in concert with receptor editing induction (135, 145).  To identify 
whether a population of pre-B cells is present in VH125Tg animals harboring targeted 
Igκs, freshly isolated bone marrow was analyzed using flow cytometry.  Figure 3-1 
shows pro/pre (B220+, IgM-), immature (B220mid, IgM+), and mature recirculating 
(B220high, IgM+) B cell populations in these lines.  The distribution of these 
compartments in VH125Tg/Vκki Tgs (Fig. 3-1, B-D) are compared to 125Tg (Fig. 3-1E) 
or IgHELMD4Tg (Fig. 3-1F) (anti-insulin or anti-HEL, respectively).  As expected, 
125Tg B and IgHELMD4Tg, which possess non-Ig-targeted Tgs, show accelerated 
development to the immature B cell stage (Fig. 3-1, E-F).  In contrast, all three 
VH125Tg/Vκki targeted Tg lines (Fig. 3-1, B-D) show a four-fold increase in the IgM- 
compartment when compared to 125Tg or IgHELMD4Tg B cells (Fig. 3-1, E-F).  The 
distribution of B cell development in each VH125Tg/Vκki line more closely resembles 
VH125Tg, in which endogenous light chains must undergo rearrangement (Fig. 3-1A).   
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Table 3-1.  Genotype Nomenclature for Heavy and Light Chain Transgene(s) 
Present 
Genotype Heavy Chain Transgene Light Chain Transgene 
WT None - endogenous None - endogenous 
VH125Tg Non-targeted, anti-insulin None - endogenous 
VH281Tg Non-targeted, non-insulin-specific None - endogenous 
VH125Tg/Vκ1ki Non-targeted, anti-insulin Targeted, anti-DNA 
VH125Tg/Vκ4ki Non-targeted, anti-insulin Targeted, anti-DNA 
VH125Tg/Vκ8ki Non-targeted, anti-insulin Targeted, anti-DNA 
125Tg Non-targeted, anti-insulin Non-targeted, anti-insulin 
IgHELMD4Tg Non-targeted, anti-HEL Non-targeted, anti-HEL 
HEL: Hen egg lysozyme 
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Figure 3-1.  VH125Tg B cells harboring Igκ-targeted Igκ transgenes are retained in 
the IgM- compartment while non-targeted transgenes are accelerated through this 
stage.   Flow cytometric analysis was used to determine B220 and IgM expression on 
freshly isolated bone marrow from VH transgenic mice with an endogenous Igκ locus 
(VH125Tg), a targeted Igκ transgene (VH125Tg/Vκ1ki, VH125Tg/Vκ4ki, and 
VH125Tg/Vκ8ki), or a non-targeted Igκ transgene randomly integrated into the genome 
(125Tg and IgHELMD4Tg).  Bone marrow B cell developmental stages are: pro/pre 
(B220+ IgM-), immature (B220mid IgM+), mature recirculating (B220high IgM+).  (A-F) 
Representative plots are shown for: VH125Tg (A), VH125Tg/Vκ1ki (B), 
VH125Tg/Vκ4ki (C), and VH125Tg/Vκ8ki (D), 125Tg (E), and IgHELMD4Tg (F), n = 
8-19 animals, percentages are indicated.  (G) Bars represent the average percentage of 
total B220+ cells of the indicated developmental stage, n=8-19 animals ± SEM. 
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The increased size of the IgM- compartment is consistent with the hypothesis that B cells 
harboring targeted Vκ initiate further IgL rearrangement to undergo receptor editing, 
rather than rapidly transiting to the immature compartment as occurs in B cells harboring 
non-targeted Vκ Tgs. 
 
A pre-B cell compartment is well-maintained in targeted Vκ transgenic 
(VH125Tg/Vκki Tg) mice 
 
The presence of a substantial population of IgM- precursors in Igκ-targeted Vκ 
mice could represent either an increase in pro- or pre-B cells.  To distinguish these 
possibilities, freshly isolated bone marrow was analyzed by flow cytometry to identify 
pro-B cells (B220+ IgM-, CD43+) and pre-B cells (B220+ IgM-, CD43-) (Fig. 3-2, A-B).  
Control comparisons were made between non-targeted Ig Vκ Tg mice (125Tg and 
IgHELMD4Tg), in which IgL rearrangement is suppressed, and mice lacking Vκ Tgs 
(VH125Tg), in which all B cells must initiate endogenous IgL rearrangement to exit the 
pre-B cell stage.  B cells which possess Igκ-targeted Vκ Tgs (VH125Tg/Vκ(1, 4, or 8)ki) 
maintain an increased percentage of pre-B cells (Fig. 3-2, D-F) compared to non-Igκ-
targeted Vκ Tg B cell models (IgHELMD4Tg and 125Tg, Fig. 3-2, G-H), and instead 
resemble VH125Tg mice (Fig. 3-2C).  As expected, non-Igκ-targeted Vκ Tg mice (Fig. 
3-2, G-H) had a clear decrease in the pre-B cell compartment compared to VH125Tg 
mice (Fig. 3-2C).  These data are consistent with a developmental delay in B cells from 
VH125Tg/Vκ(1, 4, or 8)ki mice that would be consistent with receptor editing, and 
suggest that anti-insulin VH125 can support this process. 
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Figure 3-2.  Pre-B cells are increased when VH125Tg is paired with Igκ-targeted Igκ 
transgenes compared with non-targeted Igκ transgenes.  Flow cytometry analysis 
shows B220, IgM, and CD43 expression for freshly isolated bone marrow cells.  CD43 
expression in B220+ IgM- cells identifies pro (CD43+) and pre (CD43-) B cells (A-B).  
(C-H) Representative scatter plots for a rearranged VH transgene paired with endogenous 
Igκs (VH125Tg, D), targeted Igκ transgenes (VH125Tg/Vκ1ki, D, VH125Tg/Vκ4ki, E, 
or VH125Tg/Vκ8ki, F), or a non-targeted Igκ transgene (125Tg, G, and IgHELMD4Tg, 
H).  (I ) Bars show the average percentage of pre-B cells (in B220+ IgM- gated cells) of 8-
14 animals ± SEM. 
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IgL replacement occurs in B cells possessing an anti-insulin heavy chain 
To determine if the increased pre-B cell compartment observed in VH125/Vκki 
animals coincides with receptor editing, Vκ usage was assessed in a Vκ cDNA library 
amplified from spleen B cells isolated from VH125/Vκki mice.  DNA sequencing of 
independent clones revealed that all three Igκ-targeted Vκ strains showed evidence of Vκ 
replacement: approximately one third of isolates from VH125Tg/Vκ1ki and 
VH125Tg/Vκ8ki B cells, or two thirds of isolates from VH125Tg/Vκ4ki B cells replaced 
the Tg-encoded Vκ (Table 3-2).  Vκ usage for each of the three genotypes is shown in 
Table 3-3 through 3-5.  None of the three targeted Vκ transgenic lines showed a 
detectable percentage of Igλ+ cells in the spleen, suggesting that editing to the Igλ locus is 
not occurring with any measurable frequency (not shown).  These data are consistent with 
a correlation between an increased pre-B cell compartment and induction of receptor 
editing in VH125Tg B cells harboring Igκ-targeted Vκ Tgs. 
 
VH125Tg/Vκ(1, 4 or 8)ki mice do not generate insulin-binding B cells 
A substantial proportion of VH125Tg/Vκ(1, 4, or 8)ki B cells retained the Igκ-
targeted Vκ (Table 3-2); therefore, if pairing of these Vκ with VH125 produces an 
insulin-binding specificity, insulin-binding B cells should be readily detectable, and 
might explain the substantial editing observed.  To detect these B cells in the spleen, 
B220, IgM, and insulin-binding expression was assessed in freshly isolated 
VH125Tg/Vκ1ki, VH125Tg/Vκ4ki, and VH125Tg/Vκ8ki cells using flow cytometry.  
As shown in Figure 3-3, compared with insulin-binding 125Tg B cells, VH125Tg/Vκ1ki, 
VH125Tg/Vκ4ki, and VH125Tg/Vκ8ki B cells do not measurably bind insulin, even 
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Table 3-2.  Frequency of Replacement of a Targeted Light Chain Paired with 
VH125 
Heavy Chain Transgene Light Chain Transgene % Replacement of the 
Targeted Light Chain Allele 
VH125Tg Vκ1ki (Vκ1-110, Jκ1) 30 
VH125Tg Vκ4ki (Vκ4-81, Jκ4) 65 
VH125Tg Vκ8ki (Vκ8-91, Jκ5) 40 
Percentages are based on 20 independent clones for each genotype 
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Table 3-3.  Vκ/Jκ Usage in VH125Tg/Vκ1ki Spleen B Cells 
Clone # Clone Name Vκ, Jκ Utilized 
1 1-1A2 Vκ1-110, Jκ1 
2 1-1B Vκ1-110, Jκ1 
3 1-2C Vκ1-110, Jκ1 
4 1-3AS Vκ1-110, Jκ1 
5 1-3-2A Vκ1-110, Jκ1 
6 1-3-4A Vκ1-110, Jκ1 
7 1-3-5A Vκ1-110, Jκ1 
8 1-4A Vκ1-110, Jκ1 
9 1-5A Vκ1-110, Jκ1 
10 1-5BS Vκ1-110, Jκ1 
11 1-5C Vκ1-110, Jκ1 
12 1-5D Vκ1-110, Jκ1 
13 1-6BS Vκ1-110, Jκ1 
14 1-6CS Vκ1-110, Jκ1 
15 1-1C Vκ9-120, Jκ2 
16 1-2A Vκ14-111, Jκ5 
17 1-2B Vκ14-100, Jκ2 
18 1-3BS Vκ9-120, Jκ5 
19 1-3-6A Vκ4-57, Jκ4 
20 1-4D Vκ4-61, Jκ5 
Clones which replaced the targeted allele are shaded in gray, all clones are derived from 
independent pools of B cells 
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Table 3-4.  Vκ/Jκ Usage in VH125Tg/Vκ4ki Spleen B Cells 
Clone # Clone Name Vκ, Jκ Utilized 
1 4-1A Vκ4-81, Jκ4 
2 4-3A Vκ4-81, Jκ4 
3 4-5AS Vκ4-81, Jκ4 
4 4-7CS Vκ4-81, Jκ4 
5 4-8A Vκ4-81, Jκ4 
6 4-9A Vκ4-81, Jκ4 
7 4-9B2 Vκ4-81, Jκ4 
8 4-1B Vκ19-93, Jκ1 
9 4-2A Vκ1-135, Jκ4 
10 4-2BS Vκ4-91, Jκ2 
11 4-3B Vκ17-127, Jκ2 
12 4-4AS Vκ1-135, Jκ1 
13 4-4BS Vκ1-110, Jκ2 
14 4-5B Vκ1-117, Jκ1 
15 4-6A Vκ4-91, Jκ1 
16 4-6B Vκ1-110, Jκ2 
17 4-7A Vκ4-57, Jκ4 
18 4-7B Vκ4-80, Jκ2 
19 4-8B Vκ4-72, Jκ1 
20 4-9C3 Vκ5-39, Jκ5 
Clones which replaced the targeted allele are shaded in gray, all clones are derived from 
independent pools of B cells 
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Table 3-5.  Vκ/Jκ Usage in VH125Tg/Vκ8ki Spleen B Cells 
Clone # Clone Name Vκ, Jκ Utilized 
1 8-1A Vκ8-19, Jκ5 
2 8-3AS Vκ8-19, Jκ5 
3 8-3B Vκ8-19, Jκ5 
4 8-4BS Vκ8-19, Jκ5 
5 8-6AS Vκ8-19, Jκ5 
6 8-7AS Vκ8-19, Jκ5 
7 8-7B Vκ8-19, Jκ5 
8 8-7C Vκ8-19, Jκ5 
9 8-8AS Vκ8-19, Jκ5 
10 8-8BS Vκ8-19, Jκ5 
11 8-9A Vκ8-19, Jκ5Jκ2 
12 8-9B Vκ8-19, Jκ5 
13 8-1BS Vκ4-68, Jκ2 
14 8-2A Vκ4-74, Jκ2 
15 8-2B Vκ9-120, Jκ2 
16 8-2-1B Vκ4-57, Jκ2 
17 8-4A Vκ1-110, Jκ2 
18 8-5A2 Vκ14-130, Jκ1 
19 8-5B2 Vκ1-110, Jκ2 
20 8-6BS Vκ14-111, Jκ4 
Clones which replaced the targeted allele are shaded in gray, all clones are derived from 
independent pools of B cells 
 
 73
 
 
 
Figure 3-3.  Igκ-targeted Igκ transgenes do not generate insulin-binding BCRs when 
paired with an anti-insulin IgH (VH125).  Flow cytometry was used to measure insulin 
binding in freshly isolated B220+ IgM+ spleen cells from VH125Tg (shaded, negative 
control), VH125Tg/Vκ1ki (thick black line), VH125Tg/Vκ4ki (thick dark grey line), 
VH125Tg/Vκ8ki (thin black line), or 125Tg (dashed line, positive control) upon staining 
with 5 μg/mL biotinylated insulin.  Data represent ≥ 6 animals. 
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when incubated with high concentrations of insulin (5 µg/mL; detection of insulin-
binding of 125Tg B cells is readily achieved with 0.05 µg/mL insulin).  Insulin binding 
mediated by the Igκ-targeted Igκs is essentially negative and resembles VH125Tg 
animals, in which insulin-binding cells are not detected in the periphery.  An insulin-
binding population was also not detected in bone marrow B cells, and measurable levels 
of insulin-binding Ab were not found in serum enzyme-linked immunosorbent assay 
(ELISA) (not shown).  This suggests that strong insulin reactivity is not driving the 
observed receptor editing. 
 
Insulin-specific B cells are removed from the peripheral repertoire of C57BL/6, but 
not T1D-prone NOD VH125Tg mice 
 
Although VH125Tg B cells possessing the Igκ-targeted Igκs show evidence of 
receptor editing, the question of whether insulin could drive this process was not 
resolved.  A population of insulin-binding B cells is found in the spleens of VH125Tg 
NOD mice (78, 197), but is not detectable in the spleens of C57BL/6 mice (197).  As the 
anti-insulin IgH present is identical, C57BL/6 animals should also possess the potential to 
generate insulin-binding B cells.  Flow cytometry was therefore used to identify whether 
insulin-binding B cells were present among developing bone marrow B cells in the 
C57BL/6 strain, which may not have completed receptor editing-mediated replacement of 
an insulin-reactive BCR.  To avoid studying B cells with non-specific BCR:Ag 
interactions, insulin-binding was plotted against IgMa, as a linear relationship is expected 
between Ag-binding and BCR expression, and cells were incubated with 10-fold excess 
unlabeled insulin competitor.  VH281Tg mice were used as a negative control, since 
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VH281 differs from VH125 by two amino acids which are necessary to confer insulin-
binding specificity (186).   
In NOD mice, insulin-specific B cells were detected in the bone marrow (Fig. 3-4 
E) and spleens (Fig. 3-4M) of VH125Tg, but not VH281Tg mice (Fig. 3-4, G and O).  In 
C57BL/6 mice, a small population of insulin-specific B cells was also sometimes 
detected in the bone marrow of VH125Tg (Fig. 3-4A), but not VH281Tg mice (Fig. 3-
4C).  Importantly, this population was not observed in the spleens (Fig. 3-4, I and K).  A 
statistically significant increase of insulin-specific B cells was present in the bone 
marrow of VH125Tg NOD compared with C57BL/6 mice (Fig. 3-4Q).  Interestingly, this 
percentage was significantly increased further in the spleen of VH125Tg NOD mice, as 
compared with the bone marrow (Fig. 3-4Q).  These findings suggest that anti-insulin 
VH125 can pair with endogenous IgLs to produce a small population of insulin-specific 
B cells, which are observable in the developing polyclonal repertoires in bone marrow 
from both C57BL/6 and NOD mice.  This population of insulin-specific B cells is found 
in the periphery of NOD, but not C57BL/6 VH125Tg mice, which suggests that while 
tolerance mechanisms effectively prevent insulin-specific B cells from reaching the 
periphery on the C57BL/6 background, such mechanisms fail to censor them on the NOD 
background.  In contrast, the NOD strain selects for insulin-specific B cells, as shown by 
the increased percentage present in the spleen compared with bone marrow.  Defects in 
censoring anti-insulin B cells may therefore exist in the T1D-prone NOD strain.   
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An increased frequency of insulin-specific B cells develop in vitro in the absence of 
antigen from VH125Tg NOD bone marrow, compared with VH125Tg C57BL/6 
mice 
 
An increased percentage of insulin-specific immature B cells were present in 
VH125Tg bone marrow from NOD, compared with C57BL/6 mice.  This suggests either 
that the NOD IgL repertoire is more permissive for developing anti-insulin BCR when 
paired with VH125, or that central tolerance was more rapidly and effectively removing 
such specificities from the repertoire of C57BL/6 mice.  To identify whether NOD 
VH125Tg mice spontaneously generate a higher frequency of insulin-specific B cells, 
bone marrow cells were cultured in vitro using a well-established IL-7-driven culture 
system (16, 42, 161, 163) in the absence of exogenous insulin.  In this system (depicted 
Fig. 2-2A), freshly isolated bone marrow is grown with IL-7 for 5 d to enhance pro-B cell 
proliferation while B cells that have differentiated beyond this IL-7-dependent stage die, 
leaving only Ag-naïve B cells which would not have been censored by endogenous 
insulin (122).  A population of insulin-specific B cells is observable in bone marrow 
cultured from VH125 C57BL/6 mice (Fig. 3-5A), which is significantly increased in 
VH125 NOD animals (Fig. 3-5C).  This suggests that NOD developing B cells are more 
permissive for the generation of insulin-reactive BCRs. 
 
rag-2 is elevated in anti-insulin VH125Tg-restricted, polyclonal B cells 
Increased rag expression is known to correlate with receptor editing (187), thus to 
further probe whether receptor editing is evoked in VH125Tg C57BL/6 animals, real-
time PCR was used to quantify relative rag-2 transcript levels in freshly isolated 
VH125Tg bone marrow cells.  VH281 differs from VH125 by two amino acids necessary 
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Figure 3-4.  VH125 NOD mice develop an increased frequency of insulin-specific B 
cells in the bone marrow, which accumulate in the spleen in vivo.  Freshly isolated 
bone marrow (A-H) or spleen (I-P) cells from C57BL/6 or NOD VH transgenic (anti-
insulin VH125 or non-insulin-binding VH281) are incubated with anti-B220, anti-IgM, 
and biotinylated insulin/streptavidin to detect insulin-binding B cells using flow 
cytometry.  Bone marrow scatter plots are gated on B220mid IgMa+ 7AAD- events to show 
immature B cells, spleen plots are gated on B220+ IgMa+ 7AAD- lymphocytes to show 
total B cells, plots are representative of ≥ 7 mice.  (Q) Using the gating scheme listed 
above, the percentage of positive cells observed following incubation with biotinylated 
insulin and 10X excess unlabeled insulin competitor was subtracted from cells incubated 
in the absence of competitor (e.g. Panel A – Panel B).  Results for individual mice are 
plotted, C57BL/6 are shown in black, NOD are shown in grey; VH125 bone marrow (●, 
●), VH125 spleen (▲, ▲), VH281Tg bone marrow (X, X), and VH281Tg spleen (+, +) 
are shown.  * p < 0.0001, as calculated by a two tailed t test. 
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Figure 3-5.  VH125Tg NOD mice develop an increased percentage of anti-insulin B 
cells in vitro in the absence of antigen compared with VH125Tg C57BL/6 mice.  
Bone marrow B cells from C57BL/6 or NOD VH transgenic animals (anti-insulin VH125 
or non-insulin-binding VH281) were cultured with IL-7 for 5 d to enrich for Ag-naïve B 
cells.  IL-7 was withdrawn, and cells were cultured in the absence of exogenous insulin 
for an additional 2 d.  Insulin-specific bone marrow B cells were identified using flow 
cytometry as in Fig. 4.  (A-H) Plots are representative of ≥ 6 mice.  (I) Results for 
individual mice are plotted, C57BL/6 are shown in black, NOD are shown in grey; 
VH125Tg (●, ●) and VH281Tg (▲, ▲) are shown.  * p < 0.01, ** p < 0.001, as 
calculated by a two-tailed t test. 
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Figure 3-6.  Anti-insulin VH125Tg mice show increased rag-2 transcript levels.  
RNA was harvested from freshly isolated C57BL/6 bone marrow from mice that possess 
either functionally rearranged anti-insulin (VH125Tg) or insulin-unreactive (VH281Tg) 
VH transgenes.  Real-time PCR was used to measure relative rag-2 transcript levels in 
cDNA (normalized to CD19).  Bar graphs represent the average relative rag-2, error bars 
represent SEM, n = 6-9 animals. 
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for insulin binding when the IgH is paired with an anti-insulin Igκ (186); thus high 
structural similarity and similar pairing efficiency with endogenous IgLs is expected, and 
the expression of rag stimulated by “normal” IgL rearrangement should be similar.  IgH 
Tg allelic exclusion is well maintained in these models (160), therefore IgL 
rearrangement events should exclusively account for rag expression observed (52).  As 
shown in Figure 3-6, mice possessing anti-insulin VH125 show a 28-fold increase of 
relative rag-2 expression compared to control VH281Tg B cells.  Expression of rag-2 was 
normalized to cd19 expression, a B cell lineage-specific marker.  These data suggest that 
anti-insulin VH125 may up-regulate rag, an enzyme critically involved in receptor 
editing, to elicit central tolerance through IgL replacement in vivo.  Taken together, these 
data show that B cells harboring an anti-insulin IgH replace Igκ-targeted Vκs, and 
suggest that the small protein hormone, insulin, can elicit receptor editing of insulin-
reactive B cells in a polyclonal repertoire. 
 
Discussion 
Strong BCR engagement, such as that produced by multivalent or high-affinity 
interactions, is capable of stimulating receptor editing (34, 68, 76, 207), however the 
extent to which moderate affinity interactions which do not elicit a high degree of BCR 
crosslinking can drive this process in vivo is unknown.  To address the lower threshold of 
interactions necessary for receptor editing induction, the interaction of B cells harboring 
an anti-insulin IgH paired with restricted or polyclonal IgLs were studied.  Mice 
harboring anti-insulin VH125 paired with several different Igκ-targeted Vκs show 
indirect (Fig. 3-1 and 3-2) and direct evidence (Table 3-2) of Igκ-targeted Vκ 
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replacement in peripheral B cells.  Anti-insulin B cells can be observed in freshly isolated 
bone marrow of VH125Tg C57BL/6 mice, and a discrete population is clearly observable 
following culture in the absence of insulin in vitro, which is enhanced in VH125Tg NOD 
mice, suggesting that NOD developing B cells are more permissive for generation of 
insulin-binding BCRs.  In contrast with C57BL/6 mice, in which insulin-binding B cells 
are not found in the spleen, such autoreactive cells are present in the spleens of VH125Tg 
NOD mice at an increased frequency compared with the bone marrow.  This suggests that 
in contrast with C57BL/6 mice, in which tolerance prevents insulin-binding B cells from 
reaching or surviving in the periphery, such cells appear to be positively, rather than 
negatively selected on the NOD background.  Additional studies using anti-insulin 
VH125Tg C57BL/6 B cells possessing a polyclonal IgL repertoire show increased rag-2 
expression compared with non-insulin-specific (VH281Tg) controls, which is consistent 
with increased receptor editing, perhaps to censor any anti-insulin B cells that develop.  
Together, these findings extend the importance of central tolerance in maintaining B cell 
tolerance by suggesting that a small protein hormone, such as insulin, can drive this 
process. 
Polyclonal IgL usage in VH125Tg animals complicates direct detection of IgL 
replacement events.  This problem was circumvented by generating VH125Tg/Vκki lines 
that possess Igκ-targeted Vκ Tgs, in which a known Vκ is dominantly expressed, but is 
susceptible to receptor editing-mediated replacement.  The presence of a pre-B cell 
compartment in such BCR Tg mice is associated with receptor editing induction  due to 
autoreactivity, and is not found in an autoAg-free model (145).  The finding that the pre-
B cell compartment of VH125/Vκ(1, 4, or 8)ki mice is 4-5 times greater than in mice 
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possessing non-Igκ-targeted Vκ Tgs (IgHELMD4Tg or 125Tg) is therefore consistent 
with a receptor editing-induced developmental delay (Fig. 3-1 and 3-2).  Alternatively, 
chromatin remodeling events required for Igκ locus accessibility might also account for 
the delayed developmental progression, as non-targeted Igκ genes may not require these 
events for expression.  However, replacement of 30-60% of the targeted Igκ in peripheral 
B cells (Table 3-2) provides direct evidence that receptor editing is active and likely 
contributing to the enhanced pre-B cell compartment observed.  
As all three VH125Tg/Vκki lines showed evidence of receptor editing, we 
hypothesized that VH125 confers insulin specificity to the BCRs.  However, failure to 
detect insulin-binding B cells in any of these lines (Fig. 3-3) suggests that either the 
interaction with insulin, albeit physiologically relevant, is not possible to detect with 
these methods, that an unidentified autoAg is being engaged, or that the editing observed 
is Ag-independent.  Because such possibilities are difficult to rule out in the VH125/Vκki 
models, we also studied Ag-specific interactions with insulin in VH125 animals which 
possess a polyclonal (endogenous) IgL repertoire.  Insulin-binding B cells are not 
detected in the periphery of VH125Tg C57BL/6 animals (197), which suggests either that 
VH125 does not pair with the endogenous IgL repertoire to generate insulin-binding B 
cells, or that insulin-reactive B cells are censored during development in the bone 
marrow.  In vitro culture in the absence of insulin should alleviate negative selection 
through central tolerance to circulating insulin, and thus give an accurate view of the 
frequency of insulin-binding B cells that develop from the endogenous IgL repertoire.  
Insulin-specific B cells are observed in VH125Tg C57BL/6 bone marrow that is freshly 
isolated or cultured in the absence of insulin in vitro, and this frequency is significantly 
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increased among VH125Tg NOD B cells (Fig. 3-4 and 3-5).  These findings suggest that 
while insulin-binding B cells are present in the developing repertoires of both strains, the 
IgL repertoire of NOD mice may be preferentially suited to pair with VH125 and 
generate insulin-binding B cells.  The observation that multiple polymorphisms exist in 
IgLs of the autoimmune-prone NOD strain (197) may therefore explain the enhanced 
ability to generate insulin-reactive B cells. 
Insulin-specific B cells are not found in the spleens of C57BL/6 mice (Fig. 3-4 
and (197)), suggesting that although they are present in the developing repertoire, they 
are effectively removed from the peripheral repertoire.  The mechanism(s) of tolerance 
that are operating to remove insulin-binding B cells from the periphery of C57BL/6 mice 
appear to be faulty in NOD mice, as insulin-specific B cells fail to be removed from the 
spleen (Fig. 3-4).  Furthermore, the frequency of insulin-binding B cells present in the 
developing VH125Tg NOD repertoire significantly increases in the peripheral repertoire, 
suggesting that inappropriate selection of the insulin-reactive B cells is occurring in the 
periphery (Fig. 3-4).  It does not seem likely that the culling of insulin-reactive 
specificities observed is due to deletion, as B cells with an insulin-restricted BCR 
(125Tg) which retain the autoreactive BCR do not show evidence of deletion, even 
following culture with up to 50 μg/mL insulin in vitro (Fig. 2-3), but rather undergo 
anergy in vitro (Chapter II), and following exposure to circulating insulin in vivo (160).  
It is however plausible that insulin-reactive B cells encountering endogenous insulin are 
removed from the repertoire through receptor editing. 
The hypothesis that the lack of insulin-binding B cells observed in the periphery 
of VH125Tg C57BL/6 animals is due to receptor editing is supported by the finding that 
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anti-insulin VH125Tg B cells show almost 30-fold more rag-2 expression than B cells 
that express a non-insulin-binding variety of the same IgH (VH281) (Fig. 3-6).  As a 
functionally rearranged IgH transgene suppresses rag expression required for IgH 
rearrangement (120, 182), the rag expression observed likely derives from ongoing IgL 
rearrangement.  This expression may result either from primary rearrangement of 
endogenous IgLs, or secondary rearrangement induced by receptor editing (61, 152, 187).  
A wide variety of Igκ genes are reported to pair with VH125 and related VH9 genes, so a 
general problem with chain pairing is not likely (197).  Insulin-specific B cells make up a 
small fraction of the VH125Tg repertoire, however it is possible that additional, 
unappreciated autoreactive specificities are also generated in this model, which are 
partially responsible for the elevated rag-2 expression observed. 
 Insulin is a critical autoAg in T1D (206), and represents an important class of self 
Ags for which preservation of tolerance is critical for human health.  NOD mice which 
lack B cells, or possess B cells restricted to irrelevant Ag specificities are protected from 
spontaneous development of T1D (3, 78, 173, 179), however, the presence of anti-insulin 
IgH (VH125Tg) or IgH and IgL Tgs (125Tg) promote disease development (78), 
emphasizing the key role of insulin as an autoAg.  Notably, although insulin-reactive B 
cells in the periphery are anergic, this form of tolerance is insufficient to prevent 
autoimmune disease in the NOD strain (78, 160), suggesting additional tolerance 
checkpoints may be required to prevent disease.  NOD B cells specific for HEL fail to be 
rendered anergic or undergo partial deletion in response to soluble HEL engagement, 
consistent with tolerance defects (178).  We extend these studies by implicating tolerance 
defects in VH125Tg NOD mice which fail to remove insulin-specific B cells from the 
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peripheral repertoire, through inappropriate survival and/or inefficient receptor editing.  
The percentage of anti-insulin B cells present in VH125Tg NOD spleen exceeds the 
percentage of cells that are generated in the bone marrow (Fig. 3-4), suggesting that in 
addition to a breakdown in adequate elimination of insulin-reactive B cells through 
receptor editing, defective peripheral selection of the autoreactive B cells may also 
compound disease generation in the NOD model. 
Further confirmation and characterization of how insulin stimulates receptor 
editing will be difficult using the current Tg models available.  The percentage of insulin-
binding B cells in the repertoire of VH125Tg mice is very low, and is likely rapidly 
censored through receptor editing in vivo during development.  Use of the 125Tg model, 
in which the majority of B cells bind insulin, is also problematic in the study of receptor 
editing, because the Igκ is randomly integrated into the genome and is thus not subject to 
regulatory control aimed at the Igκ locus.  These cells may initiate “frustrated” editing 
attempts which are overridden by continued expression and signaling of the Igκ Tg, and 
thus lack appreciable developmental delay at the IgM- stage of B cell development or 
altered BCR specificity.  Consistent with this notion, 125Tg B cells which do not require 
rag expression for successful BCR expression and developmental progression express 
increased rag-2 transcript levels compared with VH281Tg animals, which must up-
regulate rag to successfully rearrange an IgL (not shown).  Definitive study of insulin-
induced receptor editing would thus be greatly facilitated by the generation of an IgL-
targeted anti-insulin Tg model. 
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CHAPTER IV 
 
ANTI-INSULIN B CELLS UNDERGO RECEPTOR EDITING IN THE 
PRESENCE OF CIRCULATING INSULIN IN VIVO 
 
Abstract 
Central tolerance is critically important in censoring autoreactive B cell 
specificities that arise during B cell development.  One such mechanism, receptor editing, 
can edit the BCR of B cells that receive strong signals from highly crosslinking Ags, 
however the minimum BCR engagement threshold required to induce this process has not 
been sufficiently explored.  Insulin, a key T1D autoAg, can be used as a model autoAg to 
probe this question, as it is present at a low concentration and does not interact with the 
125Tg BCR with high affinity or avidity.  We therefore developed the Igκ-targeted 
model, Vκ125ki, to address whether endogenous insulin could stimulate receptor editing.  
Whereas ~80% of VH125/Vκ125ki B cells retain the insulin-binding specificity in the 
bone marrow in vivo, this percentage is diminished to 40% in the T1 B cell compartment 
in the spleen, suggesting that ~60% of B cells exported from the bone marrow have 
replaced the anti-insulin IgL.  A similar percentage of follicular and marginal zone B 
cells show evidence of receptor editing based on loss of insulin-binding, which was 
confirmed by sequence analysis of Vκ/Jκ usage.  An increased percentage of anti-insulin 
IgL replacement was observed in B cell clones harboring Vκ125ki paired with VH125 
compared with non-insulin-binding VH281, confirming that Ag specificity contributed to 
the receptor editing observed.  This is the first demonstration that a small protein 
hormone, such as insulin, can promote receptor editing and highlights the exquisite 
sensitivity of this pivotal central tolerance mechanism. 
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Introduction 
Autoimmune diseases develop as a result of faulty maintenance of immune cell 
tolerance.  Tolerance in the B cell compartment is actively maintained throughout B cell 
development via receptor editing, deletion, and anergy.  As 55-75% of newly formed B 
cells in humans are estimated to be autoreactive, receptor editing represents a critical 
salvage pathway in B cell development (193).  Additionally, only 10-20% of immature B 
cells formed in the bone marrow survive the maturation process long enough to emigrate 
from the bone marrow, and only 3% survive as mature B cells in the periphery (5, 57, 69, 
164).  Together, these data suggest that the majority of newly formed B cells are 
autoreactive.  The repertoire of specificities is altered between immature and mature B 
cell populations, suggesting that selection is occurring between this transition (66, 153, 
168).  Multiple checkpoints exist that serve to remove autoreactive specificities generated 
in the bone marrow; however these checkpoints are dysregulated in patients with SLE, 
thus permitting escape of autoreactive cells into the periphery (167, 205).  These findings 
suggest that central tolerance defects may promote the development of human 
autoimmune disease (167, 205), and highlight the importance of understanding how B 
cell tolerance is maintained for key autoAgs. 
 If signaling emanating from BCR surface expression is absent, due to faulty 
pairing of the IgL with the IgH (38, 54), or if the signal is too strong, due to engagement 
with Ag, receptor editing may be initiated (61, 152, 187).  This results in developmental 
retention of the B cell and prolonged activity of recombinational machinery to promote 
continued IgL rearrangement (31, 187).  Ig Tgs restrict the B cell repertoire and facilitate 
the study of Ag-specific interactions, and have been used to show that receptor editing 
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occurs upon engagement of the BCR with membrane-bound Ags, such as membrane-
bound HEL (76, 189), MHC class I (93, 187), DNA (34, 61), and type IV collagen (207).  
This form of tolerance is also stimulated by soluble HEL exposure (76, 189), for which 
the BCR has a high affinity (5 x 1010 M-1) (11).  The lower limits of the threshold for 
receptor editing induction in vivo remain to be defined; thus the key T1D autoAg, insulin, 
will be used to further probe this question. 
Anti-insulin IgH and IgL pair together in the 125Tg model to produce a B cell 
repertoire in which > 95% of the B cells bind insulin (160).  We have demonstrated that 
these B cells bind circulating insulin in vivo and thus allow the study of a physiologically 
relevant BCR:Ag interaction (160).  Classically, hormones are expected to induce clonal 
ignorance, as they are soluble proteins present at low concentrations.  Surprisingly, 
peripheral 125Tg B cells are not clonally ignorant, but rather are rendered anergic in vivo 
(160), despite the fact that circulating insulin is present at very low concentrations (up to 
1-5 ng/mL post-prandially) (56), insulin is a small, soluble protein that does not 
appreciably cross-link the BCR, and the affinity of the interaction is modest (1 x 107 M-1) 
(172).  This model has been also been used to demonstrate a role for anergy in 
maintaining tolerance to insulin in the developing B cell compartment (Chapter II). 
We show that VH125/Vκ125ki B cells undergo receptor editing in vivo, based on 
loss of the BCR insulin-binding specificity, as well as sequence analysis confirmation of 
replacement of the Igκ-targeted Vκ125 (Vκ125ki).  This does not appear to be due to 
inefficient expression of Vκ125ki, as ~80% of B cells present in the bone marrow bind 
insulin.  Whereas VH125/Vκ125ki B cells bind insulin, VH281/Vκ125ki B cells do not, 
thus allowing the contribution of Ag specificity to receptor editing to be assessed.  
 89
VH125/Vκ125ki spleen B cells show an increased frequency of Vκ125ki replacement 
compared with VH281/Vκ125ki spleen B cells, suggesting B cells capable of binding 
circulating insulin undergo a higher extent of receptor editing that is likely Ag-dependent.  
 
Materials and Methods 
 
Generation of Vκ125ki Targeting Vector 
The pSVG-125Vκ vector used to generate Vκ125 Tg mice (160) was digested 
with EcoRI and SacII to liberate the Vκ125/Jκ5 fragment which was subcloned into the 
pBluescript SK(-) vector (Stratagene) and was verified through sequencing at the 
Vanderbilt Sequencing Core.  Vκ125/Jκ5 was then amplified from this vector using the 
primers NotI FWD 5’ AAGCGGCCGCAGGGTCTGTCGAT and SalI REV 5’ 
AAAGTCGACGGATGAGTCTCCTTCTC.  The 1.6 kb Vκ125 fragment was 
subsequently cloned into NotI and SalI sites in the pVKR3-83-2NEO targeting vector, 
which was kindly provided by Roberta Pelanda, National Jewish Medical and Research 
Center, Denver, CO, and the pVKR-Vκ125ki targeting construct was verified through 
sequencing.  pVKR3-832neo differs slightly from pVKR3-83neo used to generate the 3-
83κi model (144), in that no downstream Jκ segments exist on the targeted allele. 
 
Generation of Igκ-Targeted Anti-insulin Vκ125ki Mice 
The targeting vector was linearized through digestion with ClaI.  200 µg of the 
linearized DNA was electroporated into 3.5 x 107 TL1 embryonic stem (ES) cells using 
the Bio-Rad Gene Pulser II system set at 0.800kV and the capacitance at 3.0µF.  Cells 
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were selected with 200 µg/mL G418 and 2 µM Gancyclovir.  Double-resistant colonies 
were screened by Southern blot.  The 1.6 kb EcoRI probe (144) kindly provided by 
Roberta Pelanda was hybridized to blots of SacI-digested ES cell clone DNA to identify 
endogenous (5.5 kb) and targeted (6.3 kb) allele bands.  Positive clones (33 of 458 double 
resistant clones screened) were subsequently verified through PCR using FWD 5’ 
TCTGCAAATGTCTGATGAGT and REV 5’ CTCGTGCTTTACGGTATCGC primers.  
Two clones were injected into blastocysts which were transplanted into pseudopregnant 
females, who gave birth to two lines of chimera progeny.  All of this work was performed 
with the help of the Vanderbilt Transgenic Mouse/Embryonic Stem Cell Shared 
Resource.  Chimeric males were intercrossed with C57BL/6 females and brown-coated 
progeny were screened through PCR (FWD #194 5’ GGACGTAAACTCCTCTTCA and 
REV #195 5’ CCGCTCTAGACTCGAG; Fwd #182 5’ TCTGCAAATGTCTGATGAGT 
and REV #183 5’ CTCGTGCTTTACGGTATCGC) and Southern blot analysis to 
confirm the presence of the targeted allele.  PCR was also used to confirm that the intact 
Vκ125/Jκ5 was present in targeted mice (FWD #69 5’ 
AATGGATTTTCAGGTGCAGAT and REV #88 5’ GCTCCAGCTTGGTCCCAGCA).  
Six chimeric founder males were backcrossed to WT C57BL/6 females to generate mice 
carrying the targeted Vκ125 allele.  The six independent lines of progeny were all found 
to contain the targeted allele, based on PCR and Southern blot analysis. 
 
Animals 
Vκ125ki mice were intercrossed with VH125Tg C57BL/6 females (78) to 
generate VH125/Vκ125ki offspring.  Progeny from all six founder lines exhibited similar 
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percentages of “edited” non-insulin-binding B cells as assessed by flow cytometry, which 
remained consistent at various stages of backcrossing.  One line was subsequently used 
for continued backcrossing and experiments shown.  125Tg mice which harbor 
functionally rearranged anti-insulin IgH and IgL Tgs are previously described, and have 
been backcrossed > 20 generations to the C57BL/6 background (78, 81).  C57BL/6 mice 
were purchased from Taconic Farms, IghelMD4 (HELTg) C57BL/6 mice were purchased 
from The Jackson Laboratory.  All mice were housed under specific pathogen-free 
conditions, and all studies were approved by the institutional use and animal care 
committee of Vanderbilt University.   
 
Flow Cytometry and Antibodies  
Flow cytometric analysis was performed using a FACSCalibur flow cytometer or 
LSRII (BD Biosciences).  Ab reagents (BD Pharmingen): B220 (6B2), IgMa (DS-1), 
IgMb (AF6-78), and CD43 (S7).  Insulin (Sigma) was biotinylated at pH 8.0 in bicine 
buffer using biotin N-hydroxysuccinimide ester (Sigma) and detected with streptavidin 
(BD Pharmingen).  WinMDI 2.8 software (Dr. J. Trotter, Scripps Institute, San Diego, 
CA) was used for analysis. 
 
Determination of Vκ Usage 
Spleen cells from 6-10 individual animals were positively selected with IgMa-
biotin (BD Pharmingen, DS-1) and streptavidin magnetic beads (Miltenyi) through 
autoMACS sorting (Miltenyi) to >95% IgMa+ cell purity.  RNA was isolated using the Tri 
Reagent manufacturer’s instructions (Molecular Research Center).  First strand cDNA 
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was generated from total RNA using Superscript II RT (Invitrogen) and 0.67 μg oligo-dT 
primer (Amersham Biosciences) in a standard protocol.  Vκ sequences were amplified 
from first strand cDNA using the following primers: Cκ primer - 5’GGA TAC AGT TGG 
TGC AGC ATC and VκA - 5’ATT GTK MTS ACM CAR TCT CCA, where K=G or T, 
M=A or C, S=C or G, R=A or G.  Vκ sequences were amplified using AmpliTAQ DNA 
Polymerase (2U/reaction) (Applied Biosystems), 200 nM dNTP, 1.25 mM MgCl2, 13.35 
mM Cκ and VκA primers; 94oC/1 min, 42oC/1 min, and 72oC/1 min for 40 cycles.  PCR 
product was ligated into pGEM-T Easy Vector System I plasmid (Promega).  Clones 
were sequenced by the VU Sequencing Core.  Vκ gene segment sequence alignments 
were assigned using the ImMunoGeneTics database (www.imgt.cines.fr:8104/).  
Individual clones are each derived from independent pools of RNA.   
 
Results 
 
A functionally rearranged anti-insulin Igκ transgene is targeted to the Igκ locus to 
produce a novel model to assess receptor editing in insulin-specific B cells 
 
We hypothesized that 125Tg B cells may initiate “frustrated” receptor editing 
attempts, such that receptor editing initiates, but fails to remove and replace the 
autoreactive anti-insulin Igκ Tg, which is not integrated at the Igκ locus.  To directly 
assay for receptor editing, we developed a model in which anti-insulin Vκ125, was 
targeted to the Igκ locus, as outlined in the targeting schematic (Fig. 4-1A).  As described 
in Methods, Vκ125/Jκ5 (which encodes the anti-insulin IgL of 125Tg mice) was cloned 
into the pVKRneo2 targeting vector, a derivative of that used to generate the 3-83ki line 
(144), kindly provided by Roberta Pelanda.  Electroporated ES cells were screened with 
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PCR and Southern blotting (Fig. 4-1B) and positive clones were injected into blastocysts.  
Progeny from resulting chimeras were also screened using PCR and Southern blotting 
and targeting of the anti-insulin Igκ was verified in six independent lines of mice (Fig. 4-
1, C-E).  One line was ultimately chosen for extensive backcrossing to the C57BL/6 
background. 
 
Receptor editing occurs in VH125/Vκ125ki B cells exposed to circulating insulin in 
vivo 
 
To directly assay for replacement of the Igκ-targeted anti-insulin Igκ, Vκ125ki 
mice were crossed with VH125Tg mice, which harbor a non-Ig-targeted anti-insulin IgH, 
to generate VH125/Vκ125ki mice.  As > 95% of 125Tg B cells bind insulin (which 
possess the non-Igκ-targeted version of the Igκ) (160), a similarly high percentage of 
VH125/Vκ125ki B cells should bind insulin if the targeted Vκ125ki transgene is 
dominantly expressed and receptor editing is not induced.  Expression of B220, IgMa, 
Igκ, and insulin-binding specificity was therefore assessed in freshly isolated bone 
marrow and spleen cells using flow cytometry.  As shown in Fig. 4-2A, ~70% of the 
immature (IgMa+) bone marrow B cells bind insulin.  The ~30% of IgMa+ immature B 
cells that do not bind insulin could represent cells which have undergone receptor editing, 
or cells in which dominant expression of Vκ125ki did not occur.  The percentage of non-
insulin-binding B cells in the spleen is increased to ~50% (Fig. 4-2C), suggesting that the 
insulin-binding BCR is being negatively selected during B cell maturation, perhaps 
through receptor editing.  The percentage of non-insulin-binding B cells was also
 94
 
 
 
 
Figure 4-1.  Generation of an Igκ-targeted anti-insulin Igκ transgenic model, 
Vκ125ki.  (A) Targeting vector schematic.  (B) ES Clones were digested with SacI and 
Southern blots were performed using the EcoRI probe to identify presence of endogenous 
(5.5 kb) or targeted (6.3 kb) alleles.  (C-D) Tail DNA of chimeric founder progeny was 
screened for the presence of the targeted allele by (C) Southern blot analysis as in (B), or 
(D) PCR analysis of amplified fragments using primers to detect the properly targeted 
allele (FWD #182 and REV #183 primers ; FWD #194 and REV #195 primers) or (E) 
Vκ125 (FWD #69 and REV #88 primers).  Six independent founder lines produced 
progeny which harbored the targeted allele, as assessed by both Southern blot and PCR 
analysis (not shown). 
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Figure 4-2.  VH125/Vκ125ki mice show evidence of receptor editing in the presence 
of endogenous circulating insulin in vivo.  Vκ125ki mice were intercrossed with 
C57BL/6 VH125Tg mice to produce VH125/Vκ125ki mice.  (A-B) Expression of B220, 
IgMa, Igκ, and insulin-binding were assessed in freshly isolated bone marrow cells using 
flow cytometry.  The average percentage ± SD of >10 mice of non-insulin binding 
“edited” B cells was 26.9 ± 8.4 in immature B cells (B220mid, IgMa+ Igκ+, A), and 38.4 ± 
7.6 in mature recirculating B cells (B220high, IgMa+ Igκ+, B).  (C-F) Expression of B220, 
IgMa, Igκ, CD21, CD23, and insulin-binding were assessed in freshly isolated spleen 
cells using flow cytometry.  The average percentage ± SD of non-insulin binding “edited” 
B cells was 48.3 ± 11.5 in total B cells (lymphocyte-gated, B220+, IgMa+ Igκ+, C), 61.5 ± 
11.5 in T1 B cells (lymphocyte-gated, B220+, IgMa+ Igκ+, CD21lo, CD23lo, D) 49.3 ± 
12.6 in follicular B cells (lymphocyte-gated, B220+, IgMa+ Igκ+, CD21lo, CD23high, E), 
and 64.5 ± 13.4 in marginal zone B cells (lymphocyte-gated, B220+, IgMa+ Igκ+, 
CD21high, CD23lo, F).  Similar percentages of non-insulin binding B cells were observed 
in VH125/Vκ125ki independent lines of mice derived from 6 founders (not shown).  
Averages of >10 mice are shown for each plot. 
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increased in the mature recirculating B cells present in the bone marrow (Fig. 4-2B), 
although to a lesser extent than in the spleen.   
B cells undergoing receptor editing spend an extended period of time in the 
editing-competent compartment (31), thus we hypothesize that the lower percentage of 
edited B cells present in the bone marrow is due to rapid emigration of the edited cells to 
the periphery, following successful expression of a non-autoreactive BCR.  To confirm 
this hypothesis, CD21 and CD23 expression was additionally assessed in spleen cells to 
allow identification of T1, follicular, and marginal zone B cells.  T1 B cells are recent 
bone marrow emigrants, and mature into T2 and mature B cells within 48 hours (106).  
~60% of T1 cells did not bind insulin, consistent with the hypothesis that extensive 
editing occurs in the bone marrow (Fig. 4-2D).  Edited (non-insulin-binding) B cells 
make up ~50% of the follicular B cell compartment (Fig. 4-2E), and this frequency is 
elevated to ~65% in the marginal zone (Fig. 4-2F).  The percentages of non-insulin-
binding B cells were consistent among VH125/Vκ125ki mice from multiple independent 
founder lines and at multiple backcross generations, suggesting that the mixed genetic 
background of the mice was not influencing the extent of receptor editing.  Igλ+ B cells 
were not appreciably detected in the bone marrow or spleen of VH125/Vκ125ki mice, 
suggesting that Vκ125ki expression was predominantly replaced by the endogenous Igκ 
allele, and not by switching to the Igλ locus.  These findings suggest that a small protein 
hormone, such as insulin, present at low concentrations in vivo is capable of inducing 
receptor editing. 
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VH125/Vκ125ki B cells show enhanced Vκ125ki replacement over non-insulin-
binding VH281/Vκ125ki B cells 
 
Insulin-binding is not detectable in VH281Tg/Vκ125Tg B cells (186), thus a 
similar phenotype is predicted for VH281/Vκ125ki B cells.  As assessed by flow 
cytometry, VH281/Vκ125ki B cells do not bind insulin as expected (Fig. 4-3).  We 
therefore hypothesized that insulin encounter would not induce substantial Vκ125ki 
replacement in VH281/Vκ125ki B cells in vivo, as they do not appear to bind this Ag.  To 
confirm that the receptor editing observed in VH125/Vκ125ki B cells correlates with the 
insulin-reactive specificity of the BCR, Vκ/Jκ usage was assessed in non-insulin binding 
VH281/Vκ125ki and insulin-binding VH125/Vκ125ki B cells freshly isolated from 
spleens.  IgMa+ cells were positively selected using MACS sorting to purify VH125Tg+ 
cells.  Flow cytometry analysis was used to confirm that >95% of sorted cells were 
IgMa+.  As depicted in Table 4-1, VH125/Vκ125ki B cells show a higher percentage 
(68%) of clones which utilize endogenous Vκs, compared with VH281/Vκ125ki B cells 
(40%), indicating that a higher percentage of B cells retain the targeted allele when it is 
paired with a non-insulin-specific IgH.  Individual Vκ/Jκ usage from 20 independent 
clones is depicted in Table 4-2 and 4-3.  These data are consistent with receptor editing 
enhancement by an anti-insulin specificity of the BCR.   
 
Discussion 
 The contribution of receptor editing in maintaining tolerance for insulin has 
previously not been investigated, due to limitations of available anti-insulin BCR Tg 
models.  We therefore developed a novel model in which the anti-insulin Vκ (Vκ125) 
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Figure 4-3.  VH281/Vκ125ki B cells do not detectably bind insulin.  B220, IgMa, and 
insulin-binding expression were assessed on freshly isolated bone marrow cells using 
flow cytometry.  The average ± standard deviation of three mice is as follows: (A) 
VH125/Vκ125ki, 49.2 ± 4.8, (B) VH281/Vκ125ki, 98.1 ± 0.1. 
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Table 4-1.  Frequency of Replacement of a Targeted Anti-Insulin Light Chain 
(Vκ125ki) Paired with VH125 or VH281 
Heavy Chain Transgene Insulin-binding BCR 
Specificity? 
% Replacement of the 
Targeted Light Chain Allele 
VH125Tg yes 68 
VH281Tg no 40 
Percentages are based on ≥ 20 independent clones for each genotype 
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Table 4-2.  Vκ/Jκ Usage in VH281/Vκ125ki Spleen B Cells 
Clone # Clone Name Vκ, Jκ Utilized 
1 14 Vκ4-74, Jκ5 
2 16A Vκ4-74, Jκ5 
3 16D Vκ4-74, Jκ5 
4 16L Vκ4-74, Jκ5 
5 16N Vκ4-74, Jκ5 
6 20A Vκ4-74, Jκ5 
7 20C Vκ4-74, Jκ5 
8 20D Vκ4-74, Jκ5 
9 20G Vκ4-74, Jκ5 
10 20H Vκ4-74, Jκ5 
11 20I Vκ4-74, Jκ5 
12 20J Vκ4-74, Jκ5 
13 15A Vκ17-121, Jκ5 
14 16B Vκ17-121, Jκ5 
15 16C Vκ4-57, Jκ4 
16 16J Vκ9-120, Jκ2 
17 16K Vκ4-59, Jκ5 
18 16M Vκ14-100, Jκ4 
19 20B Vκ9-124, Jκ4 
20 20L Vκ16-104, Jκ2 or 5 
Clones which replaced the targeted allele are shaded in gray, all clones are derived from 
independent pools of B cells 
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Table 4-3.  Vκ/Jκ Usage in VH125/Vκ125ki Spleen B Cells 
Clone # Clone Name Vκ, Jκ Utilized 
1 5G1 Vκ4-74, Jκ5 
2 5J2 Vκ4-74, Jκ5 
3 12C1 Vκ4-74, Jκ5 
4 12E1 Vκ4-74, Jκ5 
5 12H1 Vκ4-74, Jκ5 
6 12J1 Vκ4-74, Jκ5 
7 94M4 Vκ4-74, Jκ5 
8 5A4 Vκ4-63, Jκ4 
9 5C1 Vκ4-59, Jκ5 
10 5H4 Vκ9-120, Jκ2 
11 5L1 Vκ16-104, Jκ2 
12 12B1 Vκ5-39, Jκ5 
13 12D4 Vκ5-39, Jκ5 
14 12F1 Vκ4-68, Jκ4 
15 12I4 Vκ5-39, Jκ5 
16 12L1 Vκ4-79, Jκ2 
17 26A1 Vκ4-68, Jκ1 
18 26B1 Vκ4-91, Jκ2 
19 26C1 Vκ4-81, Jκ5 
20 26D1 Vκ4-80, Jκ4 
21 26E1 Vκ14-111, Jκ2 
22 26F2 Vκ4-50, Jκ1 
Clones which replaced the targeted allele are shaded in gray, all clones are derived from 
independent pools of B cells 
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was targeted to the Igκ locus, and is thus subject to physiologic regulation of the locus, 
such as secondary rearrangement and replacement events.  The bone marrow of 
VH125/Vκ125ki mice consists of ~30% non-insulin-binding B cells, which is elevated to 
~50% in the spleen.  The T1 B cell stage is highly transient and consists of recent bone 
marrow emigrants (106).  Sixty percent of T1 B cells are non-insulin-binding, suggesting 
that positive selection in the periphery is not responsible for the frequency of non-insulin-
binding B cells observed, but rather that receptor editing during B cell development is 
occurring.  These data suggest that the Vκ125ki transgene is dominantly expressed, and is 
replaced in a substantial fraction of peripheral B cells that have encountered physiologic 
levels of circulating insulin in vivo.  A small protein hormone, such as insulin, is 
therefore capable of eliciting receptor editing in vivo as a means for maintaining B cell 
tolerance for a key autoAg in T1D. 
 The lower frequency (~30%) of non-insulin-binding B cells present in the bone 
marrow compared with the spleen (~50%) could be due to selection and accumulation of 
non-insulin-binding B cells in the periphery, or could reflect a reduced amount of time 
that non-insulin-binding, edited B cells spend in the bone marrow relative to their insulin-
binding counterparts.  The latter possibility seems more likely, as the enhanced 
percentage of edited B cells is observable in T1 B cells that have recently exited the bone 
marrow, and also because no accumulation of non-insulin-binding B cells is observed 
between the T1 and follicular or marginal zone compartments.  Time spent in the T1 B 
cell stage is ~48h (106), so although it is possible that receptor editing may continue 
following emigration from the bone marrow, edited clones exiting the T1 stage do not 
appear to be further positively-selected in subsequent maturational stages. 
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 Although the frequency of clones that retained the targeted allele was increased in 
VH125/Vκ125ki B cells compared with VH281/Vκ125ki B cells, 40% of 
VH281/Vκ125ki B cell clones showed evidence of IgL replacement based on sequence 
analysis of Vκ/Jκ transcripts.  This could be explained either by imperfect Vκ125ki 
transgene expression dominance, or by low levels of autoreactivity present in the 
VH281/Vκ125ki BCR.  Measurable insulin-binding is not detected by flow cytometry 
analysis of these B cells, but it is possible that undetectable levels of autoreactivity, either 
for insulin or unidentified autoAgs may be present which are sufficient to drive receptor 
editing.  Such possibilities are not addressed in the current studies; regardless, this 
frequency is enhanced in VH125/Vκ125ki B cells that demonstrably bind insulin, 
suggesting that Ag specificity is playing a role in enhancing receptor editing incidence.  
The frequency of receptor editing observed based on clonal analysis of Vκ/Jκ usage 
(Table 1) is also consistent with the frequency of receptor editing as identified by non-
insulin-binding B cells identified through flow cytometry. 
 SLE-susceptibility genes appear to dampen receptor editing of anti-DNA BCRs 
(105), so it is tempting to speculate that a similar defect may be present in the NOD 
background.  Future studies will address whether differential degrees of receptor editing 
are observed in non-autoimmune (C57BL/6) versus autoimmune-prone (NOD) strains of 
mice carrying the anti-insulin VH125/Vκ125ki BCR. 
Interaction of the high affinity ligand, soluble HEL, with anti-HEL B cells (5 x 
1010 M-1 affinity, (11)) induces receptor editing in vivo (76), however the current studies 
present the first evidence to suggest that B cells recognizing cognate Ag with low avidity 
and affinity (~ 8 x 106 M-1) (172) that is physiologically regulated are subject to receptor 
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editing.  These studies thus suggest that the threshold for receptor editing is lower than 
previously appreciated, and highlight the exquisite sensitivity of developing B cells for 
Ag interaction.  Receptor editing stimulation by a wide range of BCR:Ag interaction 
strength would be consistent with previous findings reporting that receptor editing occurs 
in a high percentage of developing B cells (34, 68, 76, 167, 193).  The anti-insulin 
VH125/Vκ125ki model therefore establishes that B cell tolerance for a critical autoAg in 
T1D is regulated through receptor editing.  Future studies addressing the role of this 
process in the disease state, as well as the malleability of receptor editing induction 
during the prodrome of disease may yield important methods of therapeutic intervention 
for autoimmune disease. 
 
 105
CHAPTER V 
 
DISCUSSION AND FUTURE DIRECTIONS 
 
B cells possessing self specificities are constantly being generated in the bone 
marrow, and studies indicate that the majority of newly generated B cells are autoreactive 
(193).  These important cells of the immune system are therefore presented with the 
enormous challenge of defusing or removing potentially dangerous B cells from the 
repertoire to prevent autoimmune disease.  Given the devastating effects of many human 
autoimmune diseases, it is not surprising that multiple levels of regulation exist to control 
B cell autoreactivity.  These include central tolerance, which acts in the bone marrow to 
censor the developing B cell repertoire, and peripheral tolerance, which acts in the 
periphery as a second line of defense against autoreactive B cells that escape central 
tolerance.  The work presented in this dissertation focuses on the role that central 
tolerance plays in regulating insulin-reactive, developing B cells, as it was unknown 
whether or how central tolerance was maintained for small protein hormones.   
 
B Cell Anergy Is Induced by Non-Crosslinking Antigens 
Several Ig Tg B cell models exist in which tolerance is manifested through 
anergy.  The affinity and valency of BCR:Ag interactions range; limited models currently 
exist in which the Ag recognized by the Tg BCR is not a highly multivalent interaction.  
These include the anti-insulin Tg models generated in the Thomas lab, the anti-HEL Tg 
models (64, 76), and the anti-glucose-6-phosphate isomerase (GPI) model (77).  Two 
major categories of Ig Tgs also exist: non-Ig-targeted Tgs, which are randomly integrated 
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into the genome, and Ig-targeted Tgs, which are integrated in the physiologic loci.  The 
tolerance outcome observed in the various BCR Tg models depends on these factors.   
Anti-HEL B cells recognize HEL with a high affinity (5 x 1010 M-1), and both 
soluble (monovalent) and membrane-bound (multivalent) forms of the Ag are expressed 
by Tg mice (11, 64).  The tolerance outcome differs between the two models; soluble 
HEL induces anergy, whereas membrane-bound HEL predominantly induces deletion in 
animals harboring non-Ig-targeted BCR Tgs (64).  Ig-targeted anti-HEL Tg models also 
exist, and receptor editing is favored over deletion when membrane-bound HEL is 
encountered (76).  Evidence of both anergy and receptor editing were observed if soluble 
HEL was present (76).  Anergic anti-HEL B cells show chronic elevated intracellular 
Ca2+ oscillations, continuous translocation of NFAT to the nucleus, and activation of 
ERK (72). 
The anti-GPI model encompasses a range of high to low affinity BCR interactions 
with autoAg (77).  This diverse pool of autoreactive B cells show a range of tolerance 
outcomes, including anergy, receptor editing, and possibly clonal ignorance (77).  
Tolerance outcomes in response to non-crosslinking Ags can also be addressed using 
anti-insulin BCR Tg models.  The original 125Tg model generated in our lab consists of 
non-Ig-targeted, randomly integrated anti-insulin IgH and Igκ genes, which were 
identified from BALB/c mice immunized with insulin (51, 160, 186).  Spleen B cells 
harvested from these mice were found to be functionally silenced, as defined by many 
hallmarks of anergy.  125Tg spleen B cells show impaired or no Ca2+ mobilization 
following ionomycin, suboptimal anti-IgM, or insulin stimulation (2).  This is likely due 
to enhanced SERCA pump activity to sequester Ca2+ in the ER, based on the finding that 
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treatment of 125Tg spleen B cells with thapsigargin, an inhibitor that poisons SERCA 
pumps which pump Ca2+ into the ER from the cytoplasm inhibitor, results in increased 
ER Ca2+ release when compared with WT spleen B cells (2, 109, 123).  These cells show 
reduced IP3 levels, as well as decreased basal NFATc1 and reduced NFATc1 nuclear 
translocation following stimulation when compared with WT spleen B cells (2).  
Downstream changes are also evident, as 125Tg spleen B cells show reduced 
proliferation following stimulation with anti-IgM, anti-CD40, and LPS (1).  Development 
proceeds normally, and the marginal zone compartment is enhanced (1).  Low levels of 
circulating, Tg-derived Abs are detectable, and little production of anti-insulin Ab occurs 
spontaneously or following T cell-dependent immunization (160). 
Tg mice expressing non-Ig-targeted anti-HEL BCR and soluble HEL Tgs most 
closely mimic the 125Tg system, however, important differences exist.  The 
concentration of circulating insulin is around 1 ng/mL, which can increase 5-10 fold post-
prandially (56).  The circulating concentration of soluble HEL is ~17 ng/mL (64), which 
does not fluctuate based on physiologic demand as insulin does (56).  The affinity of the 
MD4 BCR for HEL is 5 x 1010 M-1 (11), which is significantly higher than that of the 
125Tg BCR for rodent insulin, 8 x 106 M-1 (172).  Multiple differences exist in the 
cellular mechanism of functional silencing induced as well, as highlighted above.  These 
differences, in addition to the key role that insulin plays as an autoAg in T1D (140), 
outline the importance of studying tolerance in the 125Tg BCR Tg model. 
 
Insulin Elicits Anergy in Immature Anti-Insulin B Cells 
Anergy is readily accepted as a form of tolerance that functions in the periphery 
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(64), however evidence to suggest a role during B cell development in the bone marrow 
was limited prior to these studies (13, 22).  Furthermore, it was unknown whether a small 
protein hormone, such as insulin, could induce anergy in immature anti-insulin (125Tg) B 
cells; mature 125Tg B cells are rendered anergic in vivo (1, 2, 160), but the ontogeny of 
this process was undiscovered.  Chapter II demonstrates that anergy plays a role in 
developing bone marrow B cells that encounter the non-crosslinking Ag, insulin.  125Tg 
bone marrow B cells cultured with human insulin in vitro show IgM down-regulation 
(Fig. 2-3), impaired intracellular Ca2+ mobilization in response to BCR-dependent and -
independent stimulation (Fig. 2-5), as well as impaired proliferation to anti-CD40 (Fig. 2-
4) when compared with naïve cells.  Such changes appear to occur shortly following 
exposure to insulin (Fig. 2-7), and are reversible upon Ag withdrawal (Fig. 2-8).  This 
suggests that anergy in developing B cells is dynamically regulated and maintained to 
promote a high degree of functional elasticity in the tolerant state observed in these cells.   
The bulk of the studies presented in Chapter II were performed using human 
insulin, for which the 125Tg BCR has a ~100-fold higher affinity than rodent insulin 
(172).  Technical difficulties exist that impair isolation of immature B cells exposed to 
insulin in vivo, therefore the question arises as to whether the in vitro findings translate to 
immature 125Tg B cells encountering endogenous rodent insulin.  Availability of purified 
rodent insulin was experimentally limiting, however the affinity of the 125Tg BCR for 
beef and rodent insulin is highly similar, so IgM down-regulation following culture with 
beef insulin was also assessed (Fig. 2-3B).  The ability of identical concentrations of beef 
insulin doses to promote comparable IgM down-regulation in 125Tg bone marrow B cells 
compared with human insulin suggests that even this lower affinity Ag can produce a 
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biologically important outcome.  As other tolerance outcomes are stimulated by a lack of 
surface BCR signaling, such as receptor editing in response to soluble HEL (171), I 
anticipate that rodent insulin is capable of inducing a similar state of functional 
impairment in immature B cells in vivo, given its ability to reduce surface BCR levels.  
Further confirmation that beef insulin impairs other functional responses in a similar 
manner would support this hypothesis. 
 
B Cells: Potential Type 1 Diabetes Therapeutic Target? 
It is commonly thought that effective treatment of T1D will likely require a 
multifaceted therapeutic approach.  Developing the ability to transplant islets would 
represent a key breakthrough, but autoimmune attack of transplanted islets must also be 
controlled to result in long-term insulin-independence.  T cells directly mediate β cell 
destruction (reviewed in 159), however B cells are also necessary for T1D development 
in murine disease models (3, 173).  B cell-targeted therapy has been successfully used to 
treat other autoimmune diseases (47, 74, 75, 147).  Rituximab, a B cell targeted therapy, 
was approved for treatment of rheumatoid arthritis in 2006 (reviewed in 118), so it seems 
plausible that a better understanding of how B cell tolerance is dysregulated in the disease 
state may yield key insight into the design of future therapeutics.  Trials are currently 
underway to assess Rituximab efficacy in the treatment of T1D. 
To date, the anti-insulin BCR Tg models developed by our lab (VH125Tg and 
125Tg) are the only BCR Tgs shown to be capable of promoting disease in the NOD 
mouse (1, 78); other non-islet-specific BCR Tgs actually protect against T1D generation 
 110
(78, 179).  For these reasons, this dissertation sought to elucidate how central tolerance is 
induced in developing B cells reactive with a key T1D autoAg, insulin (140).   
 
B Cell Tolerance Breaches Occur in Autoimmune Disease-Prone Mice 
 Receptor editing and deletion triggered by encounter of MHC class I or 
membrane-bound HEL in cognate B cells is intact in NOD mice, and production of 
circulating Ab is impaired in anti-HEL NOD B cells when soluble HEL is present (178).  
However, B cells recognizing soluble HEL show a more reversible anergy phenotype and 
impaired partial deletion when present on the NOD background, as evidenced by an 
increased ability of CD40 co-stimulation to rescue proliferation, suggesting that tolerance 
induction may differ in the autoimmune strain (178).  NOD T1 B cells are also more 
resistant to apoptosis than non-autoimmune strains, also suggesting that normal tolerance 
checkpoints may be dysregulated (178). 
 Whereas non-insulin-specific VH281Tg is protective, VH125Tg and 125Tg mice 
develop T1D, suggesting that the presence of insulin-specific B cells is involved in the 
disease process (1, 78).  Anti-insulin B cells are rendered anergic in the periphery of both 
C57BL/6 and NOD mice (1).  Insulin-reactive B cells form the majority (>95 %) of the 
mature peripheral repertoire of both strains (1, 160), suggesting that deletion and/or 
receptor editing are failing to remove these self specificities from the repertoire.  These 
findings imply that anergy induction is insufficient to protect against T1D generation in 
the NOD mouse, thus highlighting the importance of multiple functional arms of 
tolerance in preventing insulin autoimmunity (1).  It therefore seems likely that anergy in 
125Tg NOD mice may impair certain B cell functions, such as proliferation and plasma 
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cell differentiation, but may preserve other functions, such as Ag presentation.  B cells 
likely contribute to T1D by presenting islet Ags to autoreactive T cells (174), thus if 
125Tg NOD B cells retain the capacity to present Ags, this may explain the breach of 
immune tolerance and ultimately disease development that occurs, which depends on the 
insulin-specificity of the BCR (1, 78). 
 As previously discussed, the IgL of the 125Tg model is not targeted to the 
physiologic locus, thus it is not possible to conclude that receptor editing cannot promote 
tolerance to insulin using this model.  Receptor editing could however function to censor 
insulin-binding B cells in the VH125Tg model, as endogenous IgLs encode the BCR 
specificity, and are thus subject to replacement.  This model has the additional advantage 
of permitting the study of insulin-specific B cells in the context of a polyclonal repertoire, 
which should more closely mimic how this process occurs in a natural (endogenous) 
repertoire.   
It was previously shown that insulin-binding B cells are present in the spleens of 
VH125Tg NOD, but not C57BL/6 mice (78, 197), however it was unknown whether this 
was due to differences in the ability to generate and/or censor these specificities.  In 
Chapter III, I present findings indicating that VH125Tg C57BL/6 mice can generate 
insulin-specific B cells in the bone marrow, which are not present in the spleen in vivo 
(Fig. 3-4, A and I), suggesting that VH125 can pair with endogenous IgLs on the 
C57BL/6 background to produce an insulin-binding BCR.  It is therefore likely that the 
absence of insulin-binding B cells observed in the periphery is due to induction of one or 
more B cell tolerance mechanisms.   
Deletion of insulin-specific B cells seems unlikely, as culture with up to 50 
 112
μg/mL human insulin in vitro does not result in a reduction in cell recovery, based on cell 
counts and the percentage of B220+ cells present (Fig. 2-3).  Furthermore, as discussed in 
Chapter I, deletion typically occurs when receptor editing fails (68).  Another possibility 
is that anergy is being induced in insulin-binding B cells of VH125Tg mice, resulting in 
either a severely reduced lifespan or an inability to compete for follicular niches.  The T1 
B cell compartment is formed by recent bone marrow emigrants (5, 139); thus 
autoreactive T1 B cell survival is not influenced by follicular exclusion by competition 
with non-autoreactive cells.  The similar percentage of insulin-binding B cells present in 
the T1 versus follicular and marginal zone B cell compartments of VH125/Vk125ki mice, 
which are capable of editing the Igκ-targeted anti-insulin Igκ, suggests that insulin-
binding B cells do not exhibit a survival disadvantage in the periphery, even when 
competition from non-insulin-binding B cells exists (Fig. 4-2).  It therefore does not seem 
likely that defective survival of anti-insulin B cells would account for the lack of insulin-
binding B cells in the spleen of VH125Tg mice.   
The final potential tolerance outcome, receptor editing, is the mechanism that 
seems most probable.  Unpublished preliminary observations suggest that insulin-binding 
B cells present in the bone marrow are absent at the T1 stage of B cell development in 
VH125Tg C57BL/6 mice, thus it seems unlikely that the absence of insulin-binding B 
cells in the spleen could be due to differences in cell turnover or follicular exclusion.  
Additionally, Chapter IV formally demonstrates that circulating insulin in vivo can elicit 
receptor editing in anti-insulin VH125/Vκ125ki B cells (Fig. 4-2), thus supporting the 
likelihood that receptor editing may also function to censor anti-insulin B cells in a 
polyclonal repertoire. 
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Although it is difficult to identify which mechanism(s) of tolerance may be 
responsible for removing insulin-reactive B cells from the periphery of VH125Tg 
C57BL/6 mice, it is clear that one or more of the forms of tolerance that are functioning 
on the C57BL/6 background is/are dysregulated on the NOD background, which permits 
the development of insulin-specific B cells in the periphery of these mice.  Moreover, 
rather than removing insulin-specific B cells from the mature repertoire, VH125Tg NOD 
mice appear to positively-select for these cells, as the percentage is significantly 
increased in the spleen compared with the bone marrow (Fig. 3-4Q).  A significantly 
increased ability of VH125Tg NOD mice to generate insulin-binding B cells (compared 
with VH125Tg C57BL/6 mice) may further enhance the peripheral population of insulin-
binding B cells, and thus likelihood of T1D development in NOD mice (Fig. 3-5Q).  
These findings are summarized in a model (Fig. 5-1). 
 
A Novel BCR Transgenic Model (VH125/Vκ125ki) Shows Evidence of Receptor 
Editing in the Presence of Circulating Insulin in vivo 
 
As detailed previously, the existing 125Tg model presents major limitations for 
the study of receptor editing, as novel rearrangements at the IgL loci will not inhibit 
expression of the Vκ125 Tg integrated in a non-physiologic (non-Igκ or -Igλ) locus.  
Chapter IV describes the generation of a new model, in which Vκ125 is targeted to the 
Igκ locus.  Expression of the Igκ-targeted Vκ125ki Tg should thus be subject to normal 
regulatory mechanisms aimed at the Igκ locus.  These animals are intercrossed with 
VH125Tg mice to generate VH125/Vκ125ki mice, which should develop insulin-binding 
B cells that are subject to receptor editing.  Additional Jκ segments are not present on the 
targeted allele (Fig. 4-1), thus non-insulin-binding B cells that express the Tg IgH
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Figure 5-1.  NOD mice show faulty central tolerance and fail to remove insulin-
specific B cells from the peripheral repertoire.  Insulin-specific B cells (represented by 
black stars) develop in the bone marrow of both VH125Tg C57BL/6 and NOD mice 
amidst a polyclonal repertoire (non-insulin-specific B cells indicated by grey circles).  
The number of stars shown represent relative percentages present in the various 
compartments (actual percentages of the total repertoire are much lower).  These 
autoreactive B cells are absent in the periphery of C57BL/6 mice, suggesting that one or 
more mechanisms of tolerance are functioning to censor these cells.  This contrasts with 
NOD mice, which permit selective accumulation of insulin-specific cells in the periphery, 
which indicates a breakdown in one or more tolerance mechanisms is responsible.  The 
elevated percentage of insulin-specific B cells in the bone marrow of NOD mice suggests 
a bias towards generating insulin-reactive B cells in the developing repertoire.  Multiple 
factors therefore contribute to the generation of anti-insulin B cells in the periphery of 
VH125Tg NOD mice. 
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(confirmed by IgMa expression) must express an IgL that rearranged on the other Igκ 
allele or either of the Igλ loci.  Insulin-binding specificity of the BCR therefore provides 
a direct readout of B cell receptor editing in VH125/Vκ125ki mice. 
Chapter IV shows that circulating insulin results in Vκ125ki replacement in ~50% 
of peripheral VH125/Vκ125ki B cells.  The low percentage (~30%) of B cells which have 
replaced the insulin-binding specificity in the bone marrow is increased to ~60% in the 
T1 B cell compartment, suggesting that expression of Vκ125ki is likely dominant over 
endogenous IgLs, and that once immature B cells successfully replace the insulin-binding 
BCR, they rapidly leave the bone marrow (Fig. 4-2).  I hypothesize that the ~30% of non-
insulin-binding B cells present in the bone marrow are cells which have undergone 
receptor editing, rather than those which never expressed Vκ125ki, although future 
experiments will be required to prove this. 
Assessment of Vκ/Jκ usage showed that a higher percentage (68%) of 
VH125/Vκ125ki B cells replaced the Igκ-targeted Vκ125 Tg, compared with 40% of 
VH281/Vκ125ki B cells (Table 4-1).  VH281 differs from VH125 by two amino acids 
which are responsible for insulin-binding (186), thus VH281/Vκ125ki B cells are not 
predicted to bind insulin.  These findings therefore suggest that the increased receptor 
editing observed in VH125/Vκ125ki B cells is due to insulin reactivity of the BCR, as it 
is unlikely that pairing efficiency differences exist among the two IgHs, given their high 
degree of structural similarity.  It also confirms that poor expression of the Vκ125ki Tg 
does not solely account for receptor editing, as both strains should exhibit the same 
efficiency of Tg expression dominance.  Interestingly, VH281/Vκ125ki B cells do show 
an appreciable, albeit lower level of replacement of the Igκ-targeted Vκ125ki Tg.  One 
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possible explanation is that Vκ125ki isn’t dominantly expressed, however this seems 
unlikely, given that 70% of IgMa+ B cells in the bone marrow bind insulin, and thus likely 
express the targeted allele, at least initially (Fig. 4-2).  Another explanation is that 
VH281/Vκ125ki B cells are also autoreactive, perhaps due to undetectable, yet 
physiologically relevant interactions with insulin, or with another unidentified autoAg in 
vivo.  The data presented in this thesis do not confirm or deny these possibilities, but 
regardless of the “background” receptor editing in VH281/Vκ125ki B cells, receptor 
editing is enhanced in insulin-specific VH125/Vκ125ki B cells, supporting the conclusion 
that circulating insulin can induce receptor editing. 
Interestingly, VH281/Vκ125ki,  VH125Tg/Vκ1ki, and VH125Tg/Vκ8ki B cells 
all show a lower extent of receptor editing (30-40%), whereas VH125Tg/Vκ4ki and 
VH125/Vκ125ki B cells show a similarly higher percentage of clones that have replaced 
the targeted allele (Table 3-2 and 4-1).  It is therefore tempting to speculate that Vκ4ki 
and Vκ125ki may both confer a higher degree of autoreactivity to the BCR when paired 
with VH125.  In another study, mice possessing only the targeted Vκ4ki showed 
evidence of receptor editing, suggesting that Vκ4ki may be predisposed to interact with 
IgHs to produce an autoreactive BCR (150).  As they are both Vκ4 family members 
(Vκ4-81 and Vκ4-74, respectively), perhaps there are structural similarities among the 
targeted Igκs (Vκ4ki and Vκ125ki) that contribute to this phenotype.  Further 
characterization would be required to assess whether this explanation is correct. 
In summary, insulin is capable of eliciting multiple forms of tolerance in 
developing anti-insulin B cells following insulin exposure, including anergy and receptor 
editing.   Replacement of the anti-insulin BCR specificity is not observed in the 125Tg 
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model, thus tolerance for insulin is principally manifested through anergy in this model.  
When the anti-insulin specificity of the BCR stems from either endogenously rearranged 
light chains (VH125Tg) or an Igκ-targeted anti-insulin IgL (VH125Tg/Vκ125ki), 
receptor editing-mediated replacement of the autoreactive IgL becomes possible.  
Accordingly, replacement of the anti-insulin IgL is observed in VH125Tg/Vκ125ki 
peripheral B cells, suggesting that tolerance for insulin can also be maintained through 
receptor editing.  These findings are summarized in Fig. 5-2. 
 
Future Studies 
 The development of the VH125/Vκ125ki BCR Tg model opens the door to a 
diverse array of new questions.  Approximately half of the mature B cell repertoire have 
replaced the targeted Igκ through receptor editing, however the remaining half of the B 
cells retain the insulin-binding specificity  (Fig. 4-2).  Allelic inclusion can “dilute out” 
an autoreactive BCR on the surface of the cell, and has been shown to actually facilitate 
autoimmunity by preserving the autoreactive B cell in the repertoire in a functional state 
(100).  It is unknown whether allelic inclusion occurs in VH125/Vκ125ki B cells, which 
may thus relax the tolerance stringency imposed and allow enhanced production of 
circulating insulin Ab.  It will therefore be important to assess whether allelic inclusion is 
occurring, and whether insulin-binding VH125/Vκ125ki B cells show evidence of 
anergy. 
 Another important question which has not been addressed is whether danger 
signals, such as TLR engagement, alter receptor editing.  In general, bacteremia or 
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Figure 5-2.  B Cell Tolerance Outcomes Observed in Anti-Insulin Transgenic Mice.   Decreased BCR interaction strength 
is classically recognized to permit retention of the autoreactive BCR specificity, whereas stronger interactions result in 
removal of the specificity from the repertoire.  Both anergy and receptor editing function to censor insulin-reactive immature B 
cells.
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viremia is associated with a substantial infection, thus it seems logical that pathogen-
specific bone marrow B cells should be preserved, rather than removed from the 
repertoire.  In support of this, LPS, a TLR4 agonist, drives immature B cell proliferation 
(121).  RAG proteins are negatively regulated by cell cycle progression (102, 104), 
therefore I hypothesize that LPS stimulation of immature B cells will suppress receptor 
editing induced by cognate Ag engagement by inducing cell cycle which negatively 
regulates RAG expression, thus protecting pathogen-specific B cells from tolerance 
induction. 
Chapter III shows that insulin-binding B cells, present in the developing 
repertoires of both VH125Tg C57BL/6 and VH125Tg NOD mice, are only present in the 
periphery of VH125Tg NOD mice.  This prompts the hypothesis that the efficiency of 
receptor editing on the C57BL/6 background may be more effectively removing these 
specificities, thus the Vκ125ki line is additionally being backcrossed to the NOD 
background to answer this question.  Although some evidence exists to suggest that 
tolerance defects are present in NOD mice (178), these mice will allow us to probe 
whether receptor editing for monovalent proteins is altered in T1D-prone mice, which has 
not been addressed.  Differential receptor editing might be due to altered signaling 
threshold sensitivity of NOD versus C57BL/6 immature B cells, or perhaps in the kinetic 
window in which receptor editing must be achieved prior to bone marrow export.  
Peripheral absence (or accumulation) of insulin-reactive B cells might also be explained 
by efficiency differences of bone marrow B cell to home to the spleen among the two 
strains.  Future studies will therefore aim to identify and explain any insulin tolerance 
defects present in NOD B cells. 
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Summary 
 Small protein Ags which do not strongly engage the BCR were classically 
assumed to induce clonal ignorance, due to the expectation that they would fall below the 
biological threshold of BCR detection.  However, mature anti-insulin B cells show 
evidence of anergy in the periphery, indicating that tolerance is maintained for this 
critical T1D autoAg (1, 2, 160).  The role that central tolerance plays in preventing 
insulin autoreactivity has been explored throughout this body of work, and I find that 
multiple avenues of central tolerance can be employed to keep insulin-specific B cells in 
check, including anergy and receptor editing.  Limited data exist regarding the role of 
central tolerance for developing B cells recognizing monovalent Ags.  HEL-specific B 
cells show signs of anergy in the periphery, however these studies are the first to describe 
anergy in immature B cells recognizing monovalent Ag.  Receptor editing has also been 
described for IgHELMD4Tg B cells, however our model uses an Ag that represents a 
much lower affinity interaction; the affinity of 125Tgki for insulin in vivo is 10000 times 
lower than that of MD4Tg B cells for HEL (11, 172).  The work presented in this 
dissertation challenges the dogma of the field and shows that small protein hormones can 
elicit active tolerance maintenance in immature B cells, and thus redefines the “antigen-
sensitivity rheostat” of developing B cells.  
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